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1. Abstract
In mammals, the 5’ methylation of the cytosine base (5mC) in the genomic DNA is intimately linked 
with the regulation of gene expression. Despite its stability and heritability across cell division, 5mC 
erasure is required for the activation of developmental programs associated with extensive 
functional reprogramming. Once deposited in the genome, 5mC can be removed either through 
passive dilution during DNA replication, or through active mechanisms characterized by enzymatic 
oxidation of the methyl mark to 5’-hydroxymethylcytosine (5hmC), which can persist as such or 
undergo further oxidation and enzymatic removal. However, it is still unclear what is the relative 
contribution of each mechanism to the epigenetic control in evolving biological systems. Therefore, 
the overall aim of this thesis is to investigate the contribution of active and passive mechanisms to 
5mC and 5hmC removal in a cellular system. To explore this critical issue we used primary human T 
helper (TH) lymphocytes, in which two cellular states can be clearly identified: quiescent naive T cells, 
which are slowly or rarely proliferating, and rapidly proliferating activated T cells upon antigen 
recognition. First, we found that the 5hmC is dynamically modulated during T cell activation, indeed 
unstimulated naive T cells maintained higher levels of 5hmC compared to those of all other antigen-
experienced T lymphocytes, highlighting that DNA demethylation is a process linked to the activation 
and not to specific effector T cell subsets. Using compounds that inhibit methylation or enhance 
demethylation, we found an increased ability of the cells to produce effector cytokines, suggesting 
that DNA methylation-related processes are required for the efficient differentiation of T cells to 
effector and memory subsets. By optimizing methods to uncouple T cell activation from proliferation, 
naive T lymphocytes showed a significant loss of genomic 5hmC upon activation, even in the 
complete absence of proliferation. These results point towards a role for active processes of DNA 
demethylation in the first activation of naive T cells. On the other hand replication-dependent 
dilution was the driving force leading to 5hmC reduction in highly proliferative and already 
differentiated cells. Finally, by analyzing genome-wide DNA methylation and hydroxymethylation we 
found that these modifications change dynamically during T cell activation, and 5hmC in particular 
appeared to be differentially associated with regulatory regions of early and late response immune 
genes. Our data suggest that the usage of active vs. passive mechanisms of DNA demethylation is 
differentiation and activation stage-dependent. Specifically, active demethylation mechanisms are 
selectively involved in quiescent naive T lymphocytes prior to cell-cycle entry to maintain regulatory 
regions poised for rapid responses to physiological stimuli, while passive, replication-dependent 
dilution of the modified cytosines primarily is at work in memory T lymphocytes.  
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1. Résumé 
Chez les mammifères, la méthylation en 5’ de la base cytosine (5mC) de l’ADN génomique est 
intimement liée à la régulation de l’expression des gènes. Malgré sa stabilité et son héritabilité au 
cours des divisions cellulaires, la suppression de 5mC est requise pour l’activation de programmes de 
développement. Une fois déposée sur le génome, 5mC peut être éliminée soit par dilution passive 
lors de la réplication de l’ADN soit par des procédés actifs caractérisés par l’oxydation enzymatique 
du groupe méthyl générant la 5’-hydroxyméthylcytosine (5hmC) qui peut persister en tant que tel ou 
bien subir ultérieurement oxydation et élimination enzymatique. Toutefois, la contribution relative 
de chacun de ces mécanismes dans le contrôle épigénétique des systèmes biologiques évolutifs 
demeure incertaine. Dès lors, l’objectif de cette thèse est d’étudier la contribution des mécanismes 
actifs et passifs de la suppression de 5mC et 5hmC dans un système cellulaire. A cette fin, nous avons 
utilisé des lymphocytes humains T « helper » (TH) primaires dans deux états cellulaires distincts: les 
cellules T naives quiescentes proliférant rarement ou très lentement et les cellules T activées par 
l’antigène et proliférant vigoureusement. Nous avons établi que la 5hmC est dynamiquement 
modulée durant l’activation des cellules T, les cellules naives non stimulées maintenant des niveaux 
de 5hmC plus élevés que ceux de tous les autres lymphocytes T ayant rencontré leur antigène, 
mettant ainsi en évidence que la déméthylation de l’ADN est un procédé lié à l’activation et non pas 
à une sous-population de cellules T effectrices spécifiques. Grace à des composés inhibant la 
méthylation ou augmentant la déméthylation, nous avons pu montrer une capacité accrue des 
cellules à produire des cytokines effectrices, suggérant ainsi que les procédés relatifs à la méthylation 
de l’ADN sont requis pour une différentiation efficace des cellules T effectrices et mémoire. Après  
optimisation des méthodes pour découpler l’activation de la prolifération, les lymphocytes T naifs 
ont  montré une perte significative de la 5hmC génomique lors de l’activation et ce même en totale 
absence de prolifération, pointant vers un rôle des procédés actifs de déméthylation lors de 
l’activation des cellules T naives. D’autre part, la dilution dépendant de la réplication de l’ADN est le 
procédé principal menant à la réduction de la 5hmC pour les cellules hautement prolifératives et déjà 
différenciées. Enfin, en analysant  l’entier du génome, nous avons découvert que ces modifications 
sont dynamiques durant l’activation des cellules T et que 5hmC en particulier semble être associée à 
des régions régulatrices de gènes de la réponse immunitaire initiale. Nos résultats suggèrent que 
l’usage des mécanismes actifs vs passifs de la déméthylation de l’ADN dépend de l’état d’activation 
et de différentiation. Plus précisément, les mécanismes actifs sont impliqués sélectivement chez les 
lymphocytes T naïfs avant l’entrée dans le cycle cellulaire afin de maintenir les régions régulatrices 
prêtes pour une réponse rapide alors que la dilution passive des cytosines modifiées dépendant de la 
réplication opère principalement chez les lymphocytes T mémoire. 
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2. Human T lymphocytes 
2.1 Introduction 
The human immune system responds to invading pathogens through a network of coordinated 
reactions, constituting the immune response, against antigens, namely molecules recognized as 
foreign and dangerous. The immune response is based on two major pillars: the first is the innate 
immune response (involving phagocytic cells, dendritic cells and natural killer cells as cellular 
components), that is poised to act rapidly and it recognizes conserved molecular patterns; the 
second is the adaptive immune response that takes longer to develop and it has the specificity for 
individual unique foreign antigens. An adaptive immune response includes humoral immunity, 
mediated by antibodies secreted by B lymphocytes, and cellular immunity mediated by T 
lymphocytes. The focus of my PhD studies is the T cell compartment. T lymphocytes are 
characterized by the surface expression of antigen-specific receptors encoded by genes that are 
assembled by somatic rearrangement of germ-line gene elements to form T cell receptors (TCRs), 
recognizing both the antigenic peptide and the MHC (major histocompatibility complex) molecules 
involved in peptide displaying. Indeed, while innate immune cells and B lymphocytes recognize 
native antigens, T cells require processing and presentation of the antigen prior to recognition. Such 
antigen capture and display to T lymphocytes is accomplished by antigen presenting cells (APCs). 
Among these, dendritic cells are exceptionally efficient in inducing a T cell response. Dendritic cells 
through pathways of antigen processing convert protein antigens present in the cytosol (foreign 
antigens in the cytosol may be the products of viruses or other intracellular microbes that infect such 
cells, or tumor antigens) into peptides then loaded onto class I MHC molecules and recognized by 
cytotoxic CD8+ T cells; whereas antigens internalized from the extracellular environment are 
processed into peptides displayed by class II MHC molecules and recognized by cytokine-producing 
CD4+ helper T cells (Haskins et al., 1983). The binding of a TCR to its specific peptide-MHC complex 
triggers the activation and differentiation of antigen-inexperienced naive T cells into effector cells 
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involved in the elimination of the pathogen. However, while the majority of effector cells are 
eliminated after accomplishing their functions, some differentiated cells will remain as long-lived 
memory cells to provide rapid protection upon re-exposure to the same antigen. Memory T cells, 
according to the profile of cytokine production and tissue localization, are divided into central 
memory (TCM) and effector memory subsets (TEM) (Sallusto and Lanzavecchia, 2009). In the next 
chapters I will focus in more detail on T cell differentiation and activation and on how these 
processes are regulated at the molecular level, specifically in CD4+ T lymphocytes. 
 
2.2 Origin and development 
T lymphocytes are the components responsible for the specificity of cell-mediated adaptive immune 
responses. T cells, like all of the blood cells, initially originate from hematopoietic stem cells. As 
precursors, they migrate to the thymus where their final development and maturation takes place. 
Developing T cells in the thymus are called thymocytes.  
The process of T lineage commitment includes distinct developmental stages supported by the 
thymus’ environment, which provides all the necessary stimuli needed for proliferation and 
maturation of thymocytes, such as the expression of MHC molecules, cytokines (IL-7) and 
chemokines (CCL25, CCL19, CCL21). Each stage of T cell maturation is characterized by a specific 
localization in the thymus, by the pattern of expression of antigen receptor genes, and by the 
expression of the CD4 and CD8 coreceptors. The earliest T lineage cells, recently migrated from the 
bone marrow, are initially located in the thymus outer cortex; they are called double-negative 
thymocytes (also considered to be at the pro-T cell stage) since they lack the surface expression of 
both CD4 and CD8 (CD4-CD8-), and the TCR genes are in their germline state. Subsequently, 
successful rearrangement first of TCR β chain gene, and then of the TCR α chain gene in the double-
positive stage (CD4+CD8+ thymocytes), leads to the formation of the complete αβ TCR that is 
expressed on the cell surface together with CD3 and ζ proteins that are accessory chains needed to 
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transduce signals when TCR binds to antigen-MHC complexes (Ledbetter et al., 1987); TCR chains, 
CD3 complex and ζ chains constitute the TCR complex.  
At this stage, the cells migrate from the thymic cortex to the medulla and undergo processes of 
positive and negative selection, in order to preserve useful cells in the recognition of foreign peptide 
antigens, and eliminate potentially harmful ones that could react against the host. Positive selection 
of CD4+CD8+ TCR αβ thymocytes retains cells that recognize self-peptides complexed with self-MHC 
with low avidity; at the same time lineage commitment to CD4 or CD8 expression occurs: thymocytes 
with MHC class I-restricted TCR become CD4-CD8+ (single positive CD8), and cells with MHC class II-
restricted TCR become CD4+CD8- (single positive CD4).  On the other hand, negative selection leads 
to apoptosis of thymocytes whose receptors recognize with high avidity peptide-MHC complexes 
present in the thymus. This mechanism is at the base of the self-tolerance concept: it eliminates 
potentially self-reactive T cells preventing autoimmune reactions. Once the T lymphocyte maturation 
process is complete, cells that acquired the ability to differentiate into either antigen-inexperienced 
naive CD4+ (generally called ‘T helper cells’ that activate both humoral and cellular responses) or 
CD8+ (showing cytotoxic activity against cells infected with intracellular microbes or tumor cells) T 
cells, migrate through blood circulation to peripheral lymphoid organs and tissues (lymph nodes, 
spleen, cutaneous and mucosal immune system). Upon first encounter with foreign antigens, these 
naive cells differentiate into functionally distinct effector subsets tailored to the elimination of those 
specific antigens (Abbas et al., 2012; Rothenberg et al., 2008). 
 
2.3 T lymphocyte activation 
Naive T cells are by definition T cells that have not yet encountered a foreign antigen, and as such 
recirculate throughout the body in a resting state. It is only upon antigen recognition that naïve T 
cells become activated and acquire functional properties. Activation of naive T lymphocytes occurs in 
the T cell zone of draining lymph nodes where they normally recirculate. In particular dendritic cells 
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that encountered pathogens in epithelia or tissues and internalized their protein antigens, migrate 
there and display these foreign peptides to naive T cells.  
When the TCR complex recognizes peptides associated to MHC on an APC, there is the formation of 
an immunological synapse, a contact region that includes the signaling machinery involved in T cell 
activation: the TCR complex, the CD4 or CD8 coreceptors and costimulatory receptors (such as CD28). 
The CD4 or CD8 molecules bind to the MHC and thus recognize part of the same ligand (peptide-MHC 
complex) that interact with the TCR (Reinherz et al., 1983). The cytoplasmic tails of both CD4 and CD8 
bind the Src family kinase Lck, and the ability of these coreceptors to interact with MHC molecules 
helps these proteins to be drawn adjacent to the TCR that binds the same MHC-peptide complex on 
the APC. On the other hand, CD3 complex (composed of three polypeptide chains) and ζ chains have 
a role in signaling and not in antigen recognition. Indeed the capacity of the TCR to transduce signals 
across the membrane is mediated by the cytoplasmic tails of CD3 and ζ proteins containing ITAMs 
(immunoreceptor tyrosine-based activating motifs) [Figure 1] (Reth, 1989). The antigen recognition 
by TCR, resulting in the clustering of coreceptors with the antigen receptor, starts ITAM tyrosines 
phosphorylation by Lck (June et al., 1990; Samelson et al., 1986), that in turn triggers the activity of 
downstream tyrosine kinases leading to the activation of multiple signal transduction pathways: DAG 
(diacylglycerol)-dependent pathway leading to activation of PKC (protein kinase C); PLC 
(phospholipase C)γ1-calcium dependent pathway leading to the activation of phosphatase 
calcineurin; and small G protein-MAP (mitogen-activated protein) kinase pathways leading to 
activation of ERK (extracellular receptor-activated) and JNK (c-Jun N-terminal) kinases. As I will 
describe in the following sections, in antigen-stimulated T lymphocytes these multiple signaling 
pathways merge to activate transcription factors (TFs) that induce expression of different genes. 
Three important TFs are induced by T cell activation and have a central role in most T cell responses. 
These are NFAT (nuclear factor of activated T cells), AP-1, and NF-κB [Figure 1] (Abbas et al., 2012; 
Cantrell, 1996). 
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Antigen-induced signals (so-called signal 1) are however not sufficient for the full activation of naive 
T lymphocytes, and result in a non-responsive state (anergy) or cell death by apoptosis. Indeed, APCs 
express on their surface not only antigens but also costimulatory molecules (signal 2), essential for 
full T cell activation. The best characterized costimulatory molecules expressed on activated APCs are 
B7-1 (CD80) and B7-2 (CD86). These molecules are recognized by the receptor CD28 expressed on 
the T cell surface, that is part of the immunological synapse and acts in concert with antigen 
recognition to trigger the responses of naive T cells (Jenkins et al., 1991). The role of CD28 is on the 
one hand to amplify signals (Ras/ERK/MAP kinase pathways) from the TCR complex, but also in 
parallel to induce independent signaling pathways involving PI3 (phosphatidylinositol triphosphate) 
and Akt kinases. The final contribution of these different signaling cascades is to promote survival of 
T cells, enhance proliferation, induce cytokines production (such as IL-2) and as a consequence to 
trigger differentiation of naive T cells (Abbas et al., 2012; Smith-Garvin et al., 2009). Further signals 
(signal 3) are provided by pathogen-induced inflammatory cytokines that direct and amplify naive T 
cell differentiation and expansion. For example, a cytokine milieu containing IL-12 or IL-4 can lead to 
the generation of IFN-γ-producing TH1 cells or IL-4-producing TH2 cells [Figure 1] (Curtsinger and 
Mescher, 2010; Mosmann et al., 1986; Valenzuela et al., 2002).  
                                                              
 
                                                                                                                                                    
 
 
 
 
                                                                                                                                 
                                                                                                                                Adapted from: Simeoni et al, Clin Kidney J 2016 
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Figure 1. Main signaling pathways coupled to the TCR and co‐signaling molecules at the immunological synapse. Upon 
TCR ligation by MHC/peptide complexes on APCs, an activating signal is triggered within T cells leading to transcriptional 
activation, IL-2 production and proliferation. Additional receptors (e.g. CD4, CD28, integrins and cytokine receptors) also 
participate in this process. The orchestration of these signals results in Th differentiation into various effector and memory 
subsets. 
 
Proliferation and differentiation into effector and memory cells are events following T lymphocytes 
activation and involve changes in the expression of surface molecules, expression of cytokine 
receptors and secretion of cytokines. Regarding surface molecules, one of the earliest functional 
changes occurring is an increase in the expression of CD69, which is an early activation marker 
expressed within 1-2 hours after activation (Cebrián et al., 1988; Testi et al., 1989). The role of CD69 
is to block the exit of recently activated T lymphocytes from lymphoid organs in order to retain them 
to receive signals necessary to trigger proliferation and differentiation; indeed later, as cells divide, 
CD69 expression is reduced, allowing activated T cells to exit the lymphoid organs in order to reach 
peripheral sites of infection. Another essential early functional change occurring upon T cell 
activation is the induction of the surface expression of CD25 (IL-2Rα), that together with the IL-2Rβ 
and IL-2Rγ chains constitute the high-affinity receptor for IL-2, a change strictly connected with the 
rapid production of this cytokine. In fact, IL-2 is the major cytokine produced by naive CD4+ T 
lymphocytes early after activation representing a survival and proliferation factor (Ahmed et al., 
1997). IL-2 is a stimulus for the induction of CD25, creating a positive feedback loop, where IL-2 acts 
as autocrine growth factor, through which T cell responses amplify themselves [Figure 1]. The 
consequence of this proliferation is clonal expansion that, starting from a small number of naive 
antigen-specific lymphocytes, leads to the generation of the large number of cells required to 
eliminate the pathogen (Abbas et al., 2012; Boyman and Sprent, 2012). 
 
 
 
Chapter 2 – Human T lymphocytes 
 
 
21 
2.4 CD4+ T lymphocyte differentiation: signaling pathways and transcription 
factors 
Following the first recognition of a foreign infectious agent, naive CD4+ helper T lymphocytes 
receiving both activation and proliferation signals, will generate an array of effector T cell subsets 
involved in different types of immune response. Helper T cell differentiation is driven by the 
extracellular cytokine environment produced by activated APCs in response to encounter with 
different pathogens, along with TCR stimulation. All of these signals contribute to the expression of a 
distinct set of TFs that activate cytokine gene transcription defining a specific T helper lineage. As I 
will describe in the next chapter, the establishment of a particular transcriptome depends also on 
epigenetic changes affecting cytokine gene loci (Bevington et al., 2016), with the term epigenetics 
describing heritable modifications in gene expression without changing the DNA sequence itself.  
The family of the major CD4+ effector T cell subsets has expanded during the past two decades, and 
currently includes TH1, TH2, TH9, TH17, TH22, follicular helper T (TFH) cells, Tr1 and regulatory T (Treg) 
cells. These different subsets are defined primarily by the cytokines they produce, the specific 
pathogens they act upon and by the TFs that are necessary for their differentiation. For example, TH1 
cells are primarily important to control intracellular pathogens (such as viruses), TH2 cells act against 
helminth parasites and allergens, while TH17 cells have an important role against extracellular 
bacteria and fungi. The generation of these effector T cells underlines the specificity of adaptive 
immunity able to induce responses tailored towards the specific pathogen being recognized. TH1 
differentiation is primed by the cytokines IL-12 and IFN-γ activating the TFs STAT1 and STAT4, which 
in turn induce the expression of the master TF T-BET. For TH2 cells the main differentiation stimulus 
comes from IL-4, activating STAT6 that in turn induces GATA-3 expression. IL-4, in combination with 
TGF-β, was also found to be required for TH9 development by inducing the expression of the TFs IRF-
4 and PU.1 (Dardalhon et al., 2008). The development of TH17 cells depends on pro-inflammatory 
cytokines such as IL-6 and IL-23 that activate the TF STAT3 which functions with RORγt, the master 
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regulator for TH17 cells. IL-6 together with TNF-α, promotes also the generation of TH22 cells that 
produce predominantly IL-22 cytokine (Duhen et al., 2009). In addition to cytokines signals, AhR was 
found to be the master TF responsible for the development of TH22 cells (Ramirez et al., 2010) 
[Figure 2]. Thus, the establishment of each T helper subset is characterized by the combination of 
specific TFs (Abbas et al., 2012; Kanno et al., 2012). 
Helper T cells orchestrate host defense through their ability to produce cytokines that, by acting on 
target immune and non-immune cells, control effector responses aimed at pathogen elimination. The 
signature effector cytokine secreted by TH1 cells is IFN-γ that activates macrophages to kill 
intracellular microbes. IFN-γ triggers different signaling pathways and TFs (such as STAT1) enhancing 
microbial killing by stimulating the expression of several enzymes in the phagolysosomes of 
macrophages. Conversely the functions of TH2 cells are executed by IL-4, IL-5 and IL-13 involved in 
the stimulation of reactions mediated by IgE and eosinophils to fight helminthic infections. In 
particular IL-4 acts on B cells to stimulate the production of helminth-specific IgE antibody promoting 
the binding of eosinophils; on the other hand IL-5 activates mature eosinophils by inducing JAK2 and 
STAT3 signaling pathways leading to the release of their granule contents that help to destroy the 
parasite. TH2 cells are recognized also for their involvement in allergies and atopic illness. Similarly, 
IL-9-producing TH9 cells were shown to act in the development of allergic inflammation (Chang et al., 
2010). Most of the inflammatory actions of TH17 cells are mediated by IL-17 secretion. IL-17 
stimulates the production of chemokines and other cytokines by epithelial, endothelial, and other 
stromal cells inducing recruitment of neutrophils, which in turn represent the main defense against 
extracellular bacteria and fungi (Wan and Flavell, 2009) [Figure 2]. 
T cell help to B cells is another fundamental aspect of adaptive immunity. TFH cells localize to B cell 
follicles and they are the specialized providers of B cell help. In the early 2000s, studies on CD4+ T 
cells in human tonsils showed that T cells expressing CXCR5 display a superior capacity to induce B 
cells to produce immunoglobulins in vitro as compared to CD4+ T cells lacking CXCR5 expression. 
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Based on their localization and functions, tonsillar CD4+ T cells were defined as TFH cells. Their 
signature cytokine is IL-21, and in 2009 the TF Bcl-6 was discovered as an essential factor in defining 
TFH cells as an independent TH lineage [Figure 2] (Ueno et al., 2015).  
In addition to selective expression of cytokines, another critical aspect of differentiating T helper cells 
is to maintain immunological unresponsiveness to self-antigens, and to suppress excessive immune 
responses deleterious to the host (Sakaguchi et al., 2008). Treg cells represent the T cell subset 
essential in the control of fatal autoimmunity throughout the lifetime of an organism. Foxp3 is the TF 
expressed by Tregs, representing the master regulator of the regulatory pathway in the development 
and function of these cells [Figure 2] (Hori et al., 2003). So beyond their ability to become effector 
cells, CD4+ T lymphocytes can become Foxp3-expressing regulatory T cells that regulate immune 
homeostasis. Moreover, it was discovered a CD4+ T cell population named type 1 regulatory T cells 
(Tr1), that differed significantly from CD4+Foxp3+ Treg cells, largely due to Foxp3- phenotype. These 
CD4+Foxp3- Treg cells appeared to exert their immunosuppressive functions through the expression 
of the anti-inflammatory cytokine IL-10 (Groux et al., 1997), however, no uniquely expressed TF has 
been identified in Tr1 cells so far (Zeng et al., 2015).  
 
 
 
 
 
 
 
                                                                                                                                            
                                                                                                                                             Carbo  et al, Front Cell Dev Biol 2014 
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Figure 2. Heterogeneity of CD4+ T cell subsets. In the effector phase of the response, the effector CD4+ T cells respond to 
antigen by producing cytokines that have several functions. Cytokines inducing Th differentiation, lineage-defining TFs, 
effector cytokines are indicated.  
 
Differentiated effector cells exit secondary lymphoid organs and enter the circulation migrating 
toward the site of infection in peripheral tissues. Migration of effector T lymphocytes is allowed by 
the down-modulation of homing receptors that retain cells in the lymph nodes. One of the major 
receptor involved in maintaining T cells in the lymph node is the CCR7 chemokine receptor (Förster 
et al., 1999) that normally, binding to its ligands (CCL19 and CCL21) expressed in the T cell zones of 
secondary lymphoid organs, retains naive T cells there. Upon activation of T cells, specific 
chemokines and cytokines produced at the site of infection induce effector T cells to express 
chemokine receptors and adhesion molecules, and allowing them to preferentially home to 
inflammatory sites. Once the primary response is completed and the infection is cleared, a drastic 
contraction of the effector T cell population occurs. This happens because once the antigen is 
eliminated, the signals that allow activated lymphocytes to survive and proliferate are no longer 
available.  
However, while the majority of effector cells are eliminated after accomplishing their functions, 
some differentiated cells will persist as long-lived memory T lymphocytes. Compared to their naive 
counterparts specific for the same antigen, memory T cells have less stringent requirements for 
subsequent activation via antigenic and costimulatory receptors, an increased proliferative potential, 
and a more rapid effector response. IL-7 and IL-15 induce the expression of high levels of 
antiapoptotic proteins and stimulate low-level proliferation, both of which maintain populations of 
memory T cells during long periods (Surh and Sprent, 2008). Memory cells can traffic not only 
through draining secondary lymphoid organs, but also through peripheral tissues that are instead 
poorly accessed by naive T cells. Collectively, these characteristics allow the production of an in situ 
response to reinfection in a shorter time respect to primary response.  
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CD4+ memory T cells can be subdivided into subsets according to their different homing 
characteristics, functions and cytokine profiles (Sallusto et al., 1999, 2004). Central memory T cells 
(TCM) are characterized by high expression of the CCR7 homing receptor, consequently locating them 
in secondary lymphoid organs. TCM cells show limited effector functions but they have an increased 
potential for proliferation upon antigen re-challenge. On the other hand, effector memory T cells 
(TEM) do not express CCR7 and are thought to recirculate between blood and non-lymphoid tissues, 
or to remain poised to mobilize to the site of inflammation where they produce effector cytokines, 
such as IFN-γ, to rapidly eradicate pathogens, although their proliferative potential is more limited. 
Of note, a new lymphocyte lineage was recently identified and called tissue-resident memory T (TRM) 
cells, representing T cells that occupy tissues without recirculating (Jiang et al., 2012; Masopust et al., 
2010). TRM derive from precursors that enter the peripheral tissues during the effector phase of 
immune responses, finally remaining positioned within this compartment. TRM provide a first 
response against infections reencountered at body surfaces, where they accelerate pathogen 
clearance (Schenkel and Masopust, 2014).   
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3. Epigenetics 
3.1 Definition and epigenetic modifications 
Conrad Waddington introduced the term epigenetics for the first time in the early 1940s 
(Waddington, 2012) defining it as “the branch of biology which studies the causal interactions 
between genes and their products which bring the phenotype into being” (Waddington, 1968). Over 
time, with an improving knowledge about genetics, epigenetics has been defined as “the study of 
changes in gene function that are mitotically and/or meiotically heritable and that do not entail a 
change in DNA sequence” (Wu Ct and Morris, 2001). Thus, currently the term epigenetics refers to all 
modifications in the genome, ideally heritable from one cell to another, that induce changes in gene 
expression without affecting the DNA sequence itself (Allis and Jenuwein, 2016). At a molecular level, 
epigenetic mechanisms include primarily covalent modifications of histone tails and cytosine bases in 
the DNA, resulting in the modulation of gene expression [Figure 3]. By establishing a distinctive 
transcriptional profile, epigenetic modifications contribute to the regulation of processes such as 
differentiation and commitment towards specific cell lineages. 
 
 
 
 
 
                     
Adapted from: Zaidi et al, Mol Cell Biol 2010 
Figure 3. Epigenetic mechanisms involved in the regulation of gene expression. Epigenetic mechanisms include histone 
modifications and DNA methylation, occurring respectively at the level of histone tails and cytosines. They contribute to the 
regulation of processes such as differentiation and commitment towards specific cell lineages. 
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The nucleosome is the fundamental repeating unit of chromatin that is a tightly condensed complex 
of DNA and proteins forming chromosomes within the nucleus of eukaryotic cells. Each nucleosome 
unit particle is constituted by an octamer of core histone proteins (H2A, H2B, H3, H4) around which a 
147-bp segment of DNA is wrapped. Each histone octamer is composed of two H2.A-H2.B dimers and 
one H3-H4 tetramer; histone H1 instead is not part of the core nucleosome but it binds to the DNA 
stabilizing the core structure (Kouzarides, 2007). Nucleosome positioning, namely the localization of 
a single histone octamer on a specific region of DNA, contains already epigenetic information since 
with a specific pattern it modulates the accessibility of regulatory proteins and transcriptional 
machinery to the DNA, hence influencing gene expression. These nucleosome patterns have a 
dynamic nature, since multi-protein chromatin remodeling complexes can use ATP hydrolysis to slide 
or disassemble core histones; by doing so they can regulate transcription in a positive or negative 
manner (Bell et al., 2011; Ho and Crabtree, 2010). Histone proteins are characterized by a flexible 
amino-terminal tail protruding outward from the nucleosome, and mediating the interaction with 
other nucleosomes and regulatory factors. In particular, histone tails are subjected to covalent post-
translational modifications (PTM) such as acetylation, methylation, phosphorylation, ubiquitination, 
sumoylation, ribosylation (Rando and Chang, 2009) occurring at specific amino acidic positions. Such 
covalent modifications can alter DNA-histone interactions, impacting chromatin structure and 
recruitment of specific proteins; as a consequence histones PTMs are epigenetic marks with 
important roles in the regulation of transcription, DNA replication, DNA repair and cell cycle 
progression (Bhaumik et al., 2007) [Figure 4]. For example, acetylation is one of the most widely 
studied modifications of histones and it is catalyzed by histone acetyltransferase enzymes (HATs), 
while histone deacetylases (HDACs) are responsible for the reverse process by removing acetylation 
from histone tails. Acetylation neutralizes positive amino acids charges, reducing the affinity 
between histones and DNA and promoting gene activation. Acetylation of lysine 27 on histone 3 
(H3K27ac) is indeed a common mark of active enhancers (sequences that can be located thousands 
of base pairs away from the transcription starting site (TSS) that, when bound by TFs enhance the 
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transcription of the associated gene). Another example is provided by the methylation of histone 
tails. This process is mediated by histone methyltransferases and it can influence gene expression 
both in a positive and negative manner. Indeed, trimethylation of lysine 4 on histone 3 (H3K4me3) is 
associated with gene activation, while trimethylation of lysine 27 on histone 3 (H3K27me3) is mainly 
found in silenced genes (Strahl and Allis, 2000). Of note, histones can be modified at multiple sites at 
the same time, giving rise to a cross-talk among the different marks specifying a particular outcome.  
 
 
 
 
 
Jayani et al, Methods in Cell Biology 2010 
Figure 4. Biological roles of major histone modifications. Here is shown a summary of the best characterized histone post-
translational modifications, including histone modified site, modification pattern and proposed biological function. 
 
The only epigenetic modification truly inheritable across cell division remains however the 
methylation of the fifth carbon of cytosine in the genomic DNA (5’-methylcytosine, 5mC), since this 
modification can be copied from one generation to the next through the action of the maintenance 
DNA methyltransferase DNMT1 (Leonhardt et al., 1992a). DNA methylation occurs primarily at the 
level of CpG (Cytosine-phosphate-Guanine) dinucleotides, and it is deposited by DNA 
methyltransferase enzymes (DNMT1, DNMT3a, DNMT3b). DNA methylation is conserved among 
most major eukaryotic groups including plant, fungi and animals (Feng et al., 2010), although the 
spectrum of DNA methylation levels and patterns is very broad. For example, the nematode worm 
Caenorhabditis elegans lacks detectable 5mC, correlating with the fact that it does not encode DNMT 
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enzymes, while the fly Drosophila melanogaster shows only very low levels of 5mC. The vertebrate 
genomes have instead generally high levels of DNA methylation, which is globally distributed over 
most of the genome (Bird, 2002).  
As described in more details in the next chapters, DNA methylation plays a role in the control of gene 
expression. For example, the methylation of promoter regions generally leads to repression of 
transcription. Inhibition of transcriptional activation may result either from interference of DNA 
methylation on the recruitment of TFs, or may be caused by repressor proteins that specifically 
recognize and bind to this modification. Despite its stability, mammalian 5mC can be actively 
reversed to its unmodified state through enzymatic oxidation of 5mC to 5hmC (5’-
hydroxymethylcytosine) and further oxidation products, catalyzed by Ten-eleven translocation (TET) 
1-3 enzymes, and then followed by enzymatic removal (Wu and Zhang, 2017). Interestingly, 5hmC is 
not only an intermediate in the process of DNA demethylation, but it can also act as a stable marker 
for transcriptional regulation, enriched within gene bodies of highly transcribed genes and at 
functional regulatory elements such as enhancers  (Rasmussen and Helin, 2016). 
Aberrant DNA methylation is a common feature of human tumors, which often show extensive 
genomic hypomethylation and hypermethylation. In particular, DNA hypomethylation could 
contribute to cancer progression through loss of imprinting, inappropriate cell-type expression, 
activation of oncogenes, reactivation of transposable elements, and genomic instability. On the other 
hand, hypermethylation of tumor-suppressor genes blocks their expression triggering uncontrolled 
cell proliferation (Leoni et al., 2015a). Analogously, decreased expression of TET proteins and lower 
5hmC levels are general hallmarks of many cancer types (Leoni et al., 2015b; Lian et al., 2012). 
However, the precise impact of altered TET activity on the onset, progression, and maintenance of 
these tumors is largely unknown and remains a topic of active research (Rasmussen and Helin, 2016). 
Moreover, some biological consequences of altered methylation do not necessarily link to disease. 
Indeed, DNMT3A and TET2 in particular are frequently mutated in a number of hematological 
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malignancies, and mice lacking Dnmt3a or Tet2 gene show altered hematopoiesis and can develop 
malignancies (Quivoron et al., 2011). However, the genes encoding for DNMT3a and TET2 can also be 
found mutated in healthy, aging individuals (Busque et al., 2012), and ‘second hit’ mutations in other 
genes are typically required for progression to a fully malignant phenotype (Ko et al., 2015). 
Consequently, these evidences point towards a potential role for DNMT3A and TET2 mutations in 
increasing the risk of developing disease upon acquisition of further driver mutations.  
 In the next chapters, I will provide a detailed description of the general mechanism of DNA 
methylation and demethylation, as well as the functional roles that are known for these 
modifications in mammalian cells. 
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4. DNA methylation 
4.1 Writers of DNA methylation 
The primary sites of DNA methylation are restricted to the CpG dinucleotide context, although in 
embryonic stem (ES) and neuronal cells, cytosines outside of CpGs have also been shown to be 
methylated (Lister et al., 2009). DNA methylation is involved in the regulation of many cellular 
processes. These include mammalian development, X chromosome inactivation, genomic stability 
during mitosis, parent-of-origin imprinting, protection against spurious activity of repetitive 
elements, and regulation of gene expression. The deposition of the methyl mark is mediated by the 
activity of three DNMT enzymes: DNMT1, DNMT3A and DNMT3B (Smith and Meissner, 2013). DNMT 
enzymes methylate DNA through a conserved mechanism involving the transfer of the methyl group 
from S-adenosylmethionine (SAM), acting as methyl donor, to the fifth carbon of a cytosine residue 
to form 5mC (Santi et al., 1983) [Figure 5]. Although these enzymes are highly conserved across 
different species and share a similar structure with a N-terminal regulatory domain and a C-terminal 
catalytic domain, they have unique functions and expression patterns. During DNA replication in the 
S phase of the cell cycle, DNMT1 acts as the maintenance methyltransferase, primarily responsible 
for copying the pre-existing DNA methylation pattern from the parental DNA strand on the newly 
synthesized nascent one. On the other hand, DNMT3A and DNMT3B are de novo methyltransferases 
able to deposit the methyl mark on fully unmethylated DNA. In agreement with this, DNMT1 is 
constitutively expressed in dividing cells, it prefers hemimethylated DNA as a substrate and it 
localizes at replication foci, ensuring inheritance of methylation patterns across cell division 
(Leonhardt et al., 1992b). DNMT1 is recruited to DNA replication forks through interaction with PCNA 
(proliferating cell nuclear antigen) and UHRF1 (ubiquitin-like with PHD and ring finger domains 1), 
which directs DNMT1 to hemimethylated sites by binding to the parental methylated strand (Smith 
and Meissner, 2013). The DNMT3A/B enzymes are required for the genome-wide de novo 
methylation of DNA that occurs after embryo implantation (Li et al., 1992) and in general, the DNMT 
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family members play an important role during mammalian development and cell differentiation. 
Indeed, deletion of the Dnmt1 and Dnmt3b genes in mice is embryonically lethal, whereas gene 
knockout of Dnmt3a leads to lethality around four weeks after birth (Okano et al., 1999). In humans, 
somatic mutations in DNMT enzymes potentially contribute to malignant transformation (Zhang and 
Xu, 2017). In particular, it was found that genetic aberrations at DNMT1 locus are rare in human 
hematopoietic cancers. Similarly, mutations of DNMT3B were identified in patients affected by a rare 
autosomal recessive disease termed ICF (immunodeficiency centromeric instability and facial 
anomalies) syndrome. Conversely the DNMT3A gene was found frequently mutated in myeloid and 
lymphoid malignancies and associated with poor prognosis (Ko et al., 2015). DNMT3A and DNMT3B 
can also be distinguished by their expression pattern: DNMT3A expression is ubiquitous and can be 
readily detected in most adult tissues, whereas DNMT3B is expressed at very low levels in most 
tissues except testis, thyroid and bone marrow (Xie et al., 1999). A final member of DNMT family is 
DNMT3L that however lacks the catalytic domain. Although DNMT3L has no catalytic function of its 
own, it associates with the DNMT3A and DNMT3B and stimulates their methyltransferase activity 
during the early stages of ES cells development (Jia et al., 2007).  
 
 
 
 
 
                                                                                                                                                                                                               
                                                                                                                                                                                                              Adapted from: Li et al, J Hematol Oncol 2017 
 
Figure 5. Biochemistry of DNA methylation. Methylation of the carbon 5 (C5) of the aromatic ring of cytosines is catalyzed 
by DNMTs that transfer the methyl group from S-adenosylmethionine (SAM), acting as methyl donor, resulting in the final 
production of 5’-methylcytosine and S-adenosylhomocysteine (SAH). 
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All DNMTs share a similar multi-domain structure composed by a variable N-terminal part including 
regulatory domains, and a conserved C-terminal region that harbors the catalytic methyltransferase 
domain (MTase) responsible for DNA chemical modification. The different specific activity of DNMTs 
enzymes is reflected in their different N-terminal domains (Jurkowska and Jeltsch, 2016). For 
example, the N-terminal part of DNMT1 contains domains that specify the anchoring to 
hemimethylated substrates at the replication fork of replicating DNA (Song et al., 2011). On the other 
hand, the N-terminal part of DNMT3A/B contains principally two functional domains. The ADD 
(ATRX-DNMT3-DNMT3L) domain is essential for the interaction with H3 histone tails and is blocked 
by the histone mark for transcriptional activation H3K4me3 (Otani et al., 2009); the PWWP (proline-
tryptophane) domain (missing in DNMT3L) was shown to be essential for the targeting of the 
enzymes to pericentromeric repeats (Chen et al., 2004).  
 
4.2 DNA methylation patterns and function 
Genome wide DNA-methylation analysis showed that 60-80% of CpG sites in mammalian genomes 
are methylated, and about 10% of CpGs occur in regions characterized by an higher density of CpG 
dinucleotides called CpG islands (Smith and Meissner, 2013). CpG islands are largely resistant to DNA 
methylation, and are located primarily in the proximity of promoters of actively transcribed genes 
like housekeeping genes and developmental regulator genes (Deaton and Bird, 2011). Approximately 
60% of TSSs correspond to CpG islands. However, a small fraction of CpG island promoters become 
methylated in a tissue-specific manner during early development or in differentiated tissues, and in 
these cases methylation is associated with stable  transcriptional silencing [Figure 6] (Ambrosi et al., 
2017; Smith and Meissner, 2013). DNA methylation plays a key role in a variety of processes that 
ensure proper gene expression during development, for example in the process of genomic 
imprinting, in which hypermethylation at one of the two parental alleles leads to monoallelic gene 
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expression. Imprinted genes include the extensively studied Igfr2 (insulin-like growth factor 2 
receptor) which was identified in 1991 (Barlow et al., 1991), but also several other genes such as 
PHLDA2, PEG3, PEG10 and PLAGL1, most of which are involved in the control of fetal growth and 
behaviour after birth, highlighting the importance of DNA methylation-related processes for normal 
mammalian growth and development (Reik and Walter, 2001). DNA methylation is also essential for 
the stable silencing occurring during X-chromosome inactivation (XCI) in females; XCI is a mechanism 
of dosage compensation used in mammals to balance the expression of sex-linked genes between 
46,XY males and 46,XX females, resulting in the silencing of the majority of genes on one of the two X 
chromosomes in each somatic cell in females (Portela and Esteller, 2010). XCI is the result of a 
combination of several epigenetic mechanisms that act synergistically to maintain the X inactive 
state. Specifically, XCI involves the action of two non-coding RNAs: Xist (X-inactive specific transcript) 
and its antisense transcript Tsix. Xist is expressed exclusively from the inactivated chromosome and 
works to modulate its epigenetic silencing; it binds to the polycomb repressive complex 2 (PRC2), 
leading to the deposition of the repressive histone mark H3K27me3 thereby inactivating 
chromosome expression (Zhao et al., 2008). Expression of Xist, which sets the inactivation process, is 
followed by widespread CpG islands methylation reinforcing the chromosome silencing (Keohane et 
al., 1996; Wutz and Jaenisch, 2000). On the other hand, Tsix expression, that is silenced in the 
inactivated chromosome, is essential to restrict Xist activity on the active copy of the X chromosome, 
either by antisense-binding of Xist or through the recruitment of enzymes catalyzing DNA-
methylation of the Xist promoter, which results in its silencing (Panning and Jaenisch, 1996). The 
importance of DNA methylation in contributing to genome stability is further highlighted by its role in 
the silencing of non-coding sequences, including pericentromeric repeats and repetitive elements, 
such as long or short interspersed transposable elements (LINEs or SINEs), characterized by a latent 
transcriptional potential [Figure 6]. The repression of pericentromeric satellite repeats is essential for 
a correct chromosome alignment, segregation and integrity during mitosis. Transposable elements, 
since they often contain strong promoters elements, are constitutively hypermethylated to prevent 
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their activity, which may cause chromosomal instability, translocations and gene disruption (Smith 
and Meissner, 2013).  
 
 
 
 
 
                                                                                                                                                                                                                      Carrio’ et al, Front Aging Neurosci. 2015 
 
Figure 6. Schematic representation of the mammalian methylome and role in gene expression. CpG island promoters are 
usually protected from DNA methylation and are prone to active transcription. CpG-poor regions (intergenic) and repetitive 
elements are typically methylated, with the exception of enhancers and CpG-poor promoters that can be differentially 
methylated in a cell type-specific fashion. Intragenic regions can also be differentially methylated leading to specific cell-
type transcripts. MBPs: methyl-binding proteins; TFs: transcription factors. 
 
4.3 DNA methylation and its readers: a role in gene expression 
While the majority of genomic methylation patterns remain stable in cells after development, 
modifications of levels of DNA methylation can also occur dynamically at specific regulatory regions, 
to modulate gene expression during cell differentiation and in response to environmental signals. 
The functional read-out of DNA methylation is context dependent; in general, CpG island methylation 
is associated with gene silencing. Indeed DNA methylation was found in most CpG rich promoters 
and in low-to-intermediate CpG distal regulatory regions such as enhancers of inactive genes (Jones, 
2012). In particular, the presence of methylation marks at TSSs is usually associated with lack of gene 
transcription that could be mediated either through attraction or repulsion of regulatory factors. For 
example, methylated-CpGs attract methyl-CpG-binding domain (MBD) proteins (MBD1,2,4 and 
MeCP2) in a sequence-independent manner (Hendrich and Bird, 1998). Binding of MBD proteins 
could directly prevent TFs from binding because of steric hindrance or through the recruitment of 
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histone modifying and chromatin remodeling complexes [Figure 6] (Baubec et al., 2013). Conversely 
other readers recognize methyl-CpGs by zinc-finger domains in a sequence-dependent context; these 
factors include KAISO, ZBTB4, ZBTB38 and ZFP57 (Filion et al., 2006). For example, by recognizing the 
methylated TGCCGC hexanucleotide, ZFP57 recruits its cofactor KAP1 and other chromatin and DNA 
modifiers to methylated, imprinted regulatory regions. This general mechanism resulted to be 
important in the maintenance of DNA methylation at imprinting control regions during early 
embryonic development, protecting specific loci against DNA demethylation (Quenneville et al., 
2011). On the other hand many factors known to recognize CpG-containing sequences are not able 
to bind when the cytosine is methylated. For example by analyzing the effect of DNA methylation on 
TF binding in mouse ES cells, it was shown that NRF1 (nuclear respiratory factor 1) is a methylation-
sensitive TF; indeed, the induction of local hypermethylation led to a loss of NRF1 binding, 
demonstrating the competition between TF binding and CpG methylation (Domcke et al., 2015). 
Methylation of DNA occurs also at lower CpG density regions called “CpG islands shores” located up 
to 2 kb upstream of CpG islands (Irizarry et al., 2009). The methylation of CpG islands shores is 
associated with the transcriptional inactivation of the downstream gene (Portela and Esteller, 2010). 
Most of the tissue-specific DNA methylation patterns occur at the level of CpG island shores, and 
70% of differentially methylated regions during developmental reprogramming were indeed found to 
be associated with them (Doi et al., 2009). As mentioned before, the read-out of DNA methylation is 
context-dependent and DNA methylation does not necessarily and invariably correlate with 
transcriptional repression. For instance, gene body methylation usually positively correlates with 
gene expression. Specifically, it was shown that DNMT3B, by recognizing H3K36me3 (histone H3 
lysine 36 trimethylation), participates in the maintenance of gene body methylation (Baubec et al., 
2015), and DNMT3B-dependent intragenic DNA methylation appeared to protect the gene body from 
spurious RNA polymerase II entry, avoiding cryptic transcription initiation from internal exons (Neri 
et al., 2017). 
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4.4 DNA demethylation 
Despite its stability and heritability across cell division, dynamic changes in 5mC deposition are 
observed during development and differentiation, and are necessary for the establishment of stable 
cell-specific gene expression programs. Hence, DNA demethylation (removal of the methyl mark) is 
an integral component of the epigenetic regulatory network (Ambrosi et al., 2017). 
 
4.4.1 Passive versus active DNA demethylation 
Once deposited in the genome, 5mC can be erased either through active or passive mechanisms 
[Figure 7]. Passive DNA demethylation is based on the dilution of the methyl mark through DNA 
replication during cell division. Specifically, DNMT1 is needed to methylate hemimethylated sites that 
are generated during DNA replication, and the absence of a functional DNA methylation 
maintenance machinery leads to 5mC dilution during successive rounds of cell divisions (Wu and 
Zhang, 2017). On the other hand, active DNA demethylation is potentially a replication-independent 
process involving iterative enzymatic oxidation steps leading to the modification of 5mC and its 
replacement with an unmodified cytosine. In particular, in mammals active DNA demethylation is 
mediated by the enzymatic activity of TET (1-3) proteins. The 5mC mark is first oxidized by TET 
enzymes to 5hmC and then to further oxidation products (5-formylcytosine, 5fC and 5-
carboxylcytosine, 5caC) (Ito et al., 2010; Tahiliani et al., 2009). These oxidized products are 
recognized and excised by the thymine-DNA-glycosylase (TGD) enzyme, creating abasic sites that are 
replaced with unmodified cytosines through mechanism of base excision repair (BER) (He et al., 
2011). The deposition of 5hmC can also have a role in the induction of passive DNA demethylation 
since DNMT1 does not efficiently recognize 5hmC-modified bases (Valinluck and Sowers, 2007). 
Consequently TET-mediated oxidation of the methylation mark could trigger passive replication-
dependent DNA demethylation (Rasmussen and Helin, 2016; Valinluck and Sowers, 2007).  
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In the next section I will describe the discovery, catalytic activity and role in gene expression of TET 
proteins and 5hmC. 
 
 
 
 
 
 
 
 
 
 
 
Huang et al, Trends Genet. 2014 
Figure 7. Overview of DNA methylation and demethylation pathways in mammals. Active demethylation is achieved by 
iterative oxidation of the methyl group of 5mC by TET proteins and restoration of unmodified cytosines. On the other hand, 
passive demethylation of modified cytosines, 5mC (TET-independent) or 5hmC (TET-assisted), is based on the dilution of the 
methyl mark through DNA replication during cell division. 
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5. DNA hydroxymethylation 
5.1 Discovery of 5hmC and TET proteins 
The first identification of 5hmC in vertebrates occurred in 1972, when it was identified in the DNA of 
rat, mouse and frog brain and in rat liver and spleen. The occurrence of 5hmC was identified by 
paper chromatography, UV spectra in acid and alkaline solutions and by its conversion into 5-
hydroxymethyluracil (5hmU) (Penn et al., 1972). However, other researchers failed to replicate these 
initial findings in later studies (Kothari and Shankar, 1976), and 5hmC was thought to be the by-
product of oxidative DNA damage with no established functional role (Tardy-Planechaud et al., 1997). 
It took more than 30 years to confirm the presence of 5hmC as a stable DNA modification and to gain 
insights into its molecular function as epigenetic mark. A turning point occurred in 2009, when by 
taking advantage of more advanced analytical techniques, such as 2D thin layer chromatography 
(TLC) and high-pressure liquid chromatography (HPLC) coupled to mass spectrometry analysis, 5hmC 
was rediscovered in Purkinje and granule neuronal nuclei of adult mouse brains (Kriaucionis and 
Heintz, 2009). At the same time, another research group independently observed 5hmC to be 
abundant in mouse ES cells (Tahiliani et al., 2009). Tahiliani et al. used bioinformatic tools to predict 
that TET (1-3) proteins would likely oxidize 5mC to 5hmC. Specifically, the prediction that TET 
enzymes might have DNA-modifying activity was based on the analysis of Trypanosoma brucei J-
binding protein (JBP) 1 and 2. JBPs are Fe2+-  and 2-oxoglutarate (2-OG)-dependent dioxygenases that 
catalyze the oxidation of the methyl group of thymine resulting in the production of 5hmU. In 
protists, 5hmU can be further glycosylated producing the so-called “base J” (β‐D‐D‐glucosyl‐
hydroxymethyluracil). Like 5mC, base J was shown to be associated with gene silencing (Borst and 
Sabatini, 2008). By performing a computational search for homologs of JBP1 and JBP2, mammalian 
TET1 enzyme was thereby shown to be involved in the modification of 5mC (Tahiliani et al., 2009). 
Notably, human TET1 was initially identified in 2003 as a fusion partner with MLL1 (mixed-lineage 
leukaemia 1) gene; this fusion results from a translocation, found in rare cases of acute myeloid and 
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lymphocytic leukaemia, between human chromosome 10 and chromosome 11 (Lorsbach et al., 
2003). However, despite a potentially important role in malignant transformation, no functional roles 
were associated to TET1. Following the initial work on the discovery of TET1 as an enzyme able to 
modify 5mC to 5hmC, the other two TET family proteins, TET2 and TET3, were also shown to possess 
5mC oxidizing activity (Ito et al., 2010). In summary, work performed by Tahiliani et al. proposed 5mC 
oxidation products as intermediates in the conversion from 5mC to the unmethylated cytosine, 
providing the first evidences for a pathway of active DNA demethylation in mammals. So the 
discovery of 5hmC and TET proteins represents the major breakthrough in the epigenetic field of the 
last years, providing a new perspective on how DNA modification influences the regulation of gene 
expression. 
 
5.2 Levels and distribution of 5hmC 
Mass spectrometry analyses suggest that, unlike 5mC, the levels of 5hmC are highly variable in 
different mammalian tissues (Ito et al., 2011). Consistent with the fact that the highest recorded 
levels of 5hmC were identified in the brain, 5hmC was found to be most abundant in cerebellar 
Purkinje neurons, where it comprises nearly 40% of the level of 5mC (Kriaucionis and Heintz, 2009). 
Moreover, in murine ES cells about 5-10% of 5mC is converted to 5hmC (Tahiliani et al., 2009). In 
contrast, somatic tissues such as kidney, heart, spleen and thymus contain medium to low levels of 
5hmC compared to neuronal tissues (Bachman et al., 2014; Globisch et al., 2010). Globally, the 
content of 5hmC was shown to vary across different mouse tissues regardless of the levels of 5mC 
observed in those same tissues (Nestor et al., 2012). Such 5mC-independent distribution suggested 
that 5hmC may be not only an intermediate in the process of DNA demethylation, but it may 
represent a stable epigenetic mark in its own right. Concordant with this idea a recent study, using 
stable isotope labelling of cytosine derivatives in the DNA of mammalian cells followed by 
ultrasensitive tandem liquid-chromatography mass spectrometry, showed that the majority of 5hmC 
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is a stable modification, as opposed to a transient intermediate (Bachman et al., 2014). In contrast to 
DNA methylation, which occurs immediately during replication, 5hmC appeared to form slowly 
during the first 30 hours following DNA synthesis. Moreover isotopic labelling of DNA in mouse 
tissues confirmed the stability of 5hmC in vivo (Bachman et al., 2014). 
 
5.3 TET proteins: expression and catalytic activity 
Functional evidences suggest that TET proteins are crucial for different biological processes, including 
zygotic epigenetic reprogramming, pluripotent stem cell differentiation, and hematopoiesis. 
Accordingly certain mutations in TET proteins were found to be associated with the onset of 
hematological diseases and with a wide variety of human solid tumors. In particular, TET1 is highly 
expressed in ES cells and its expression is reduced as soon as the cells are differentiated into 
embryoid bodies (Koh et al., 2011). On the other hand, TET2 is expressed at lower levels in ES cells 
but it increases upon cell differentiation, and it shows robust expression in numerous differentiated 
organs and adult tissues. Finally, TET3 is highly expressed in the zygote (Pastor et al., 2013). Genetic 
knockout mouse models underlined the physiological importance of TET proteins during 
development. Even though Tet1 and Tet2 were shown to regulate murine ES cell lineage 
specification, deletions of either Tet1 (Dawlaty et al., 2011) or Tet2 (Moran-Crusio et al., 2011) 
resulted in viable mice with normal embryonic and postnatal development; in contrast, mice with 
constitutive deletion of Tet3 died perinatally (Gu et al., 2011). These findings suggested that Tet3 
may have a unique role during early stages of embryonic development that cannot be compensated 
by the other TET proteins. When generating double-knockout mice deficient for both Tet1 and Tet2, 
it was noticed that, while some survived and developed normally, the majority died perinatally and 
showed a wide spectrum of defects such as exencephaly, growth retardation and compromised 
imprinting (Dawlaty et al., 2013). In contrast, deletion of both Tet2 and Tet3 resulted in the rapid 
onset of an aggressive myeloid leukemia (An et al., 2015). Finally, the successful generation of 
Tet1/2/3 triple-knockout (TKO) ES cells underlined how the interplay between the different TET 
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proteins activity is central for supporting embryonic development. In fact, the combined deficiency of 
all three TET proteins depleted 5hmC from the genome and impaired ES cell differentiation, leading 
to the formation of poorly differentiated TKO embryoid bodies and teratomas (Dawlaty et al., 2014). 
Considering that single-knockout and some double-knockout survive until adulthood, it was 
hypothesized the possible late onset of phenotypes; indeed, loss of Tet2 led to normal development, 
and only around at 1 year of age mice showed dysregulated hematopoietic stem cells and 
subsequent development of myeloid malignancies (Li et al., 2011), whereas Tet1 deficiency led to 
dysregulated B-cell lineage differentiation (Cimmino et al., 2015). In agreement with the mouse data, 
TET1 and TET2 are involved in cancer development in humans. TET1 was reported to function as an 
oncogene in MLL-rearranged leukemias (Huang et al., 2013), while TET2 acts as a tumor suppressor in 
all hematopoietic cell types, since deletions and loss-of-function mutations of the TET2 gene are 
associated with the development of lymphoid malignancies, myeloid leukemias, and 
myeloproliferative neoplasms (Ko et al., 2015). 
As for the general structure of TET proteins, these enzymes are 2-OG and Fe2+-dependent 
dioxygenases. All TET proteins contain a conserved DSBH (double-stranded β-helix) domain, a 
cysteine-rich domain that wraps around the DSBH core to stabilize the overall structure and TET-DNA 
interaction, and binding sites for the cofactors Fe2+ and 2-OG that together form the catalytic core 
region in the C-terminus (Iyer et al., 2009). In addition to their catalytic domain, TET1 and TET3 
contain an N-terminal CXXC domain (a Zn2+-chelating domain characterized by the signature amino 
acid sequence CGXCXXC(X)NC in which X represents any amino acid) through which they are most 
likely recruited to genomic DNA target sites [Figure 8]. The CXXC domain preferentially binds to 
unmethylated CpG sequences in vitro, and it is frequently found in proteins preferentially binding at 
CpG-rich promoters and CpG islands (which are mainly unmethylated) (Ko et al., 2013; Xu et al., 
2011, 2012; Zhang et al., 2010). Differently from TET1 and TET3, during evolution TET2 underwent a 
chromosomal inversion event in which the exon encoding for the CXXC domain was detached and 
became a separate gene encoding IDAX (Ko et al., 2013), resulting to be the interacting partner of 
 Chapter 5 – DNA hydroxymethylation 
 
 
51 
TET2 for the recruitment to unmethylated DNA, predominantly at CpG islands (Iyer et al., 2009). 
Interestingly, the CXXC domain is able to regulate the levels of DNA methylation by preventing 
unwanted DNMTs activity in murine ES cells. Specifically, it was shown that TET1 controls levels of 
DNA methylation in two ways: first by binding to CpG-rich regions through the CXXC domain, hence 
excluding DNMT1 binding and preventing its methyltransferase activity, and second through the 
conversion of 5mC to 5hmC (Xu et al., 2011). Apart from site-specific recruitment, the activity of TET 
enzymes can be modulated at a global level in the presence of specific cofactors and PTMs. For 
example, vitamin C (ascorbic acid) was shown to stimulate the catalytic activity of TET enzymes in 
both cultured cells and mouse tissues (Blaschke et al., 2013). The underlying mechanism is likely to 
involve the interaction of vitamin C with the catalytic domain of TET enzymes, providing a local 
reducing environment that increases the recycling efficiency of the Fe2+ cofactor (Yin et al., 2013). 
Regarding PTMs, TET enzymes can be monoubiquitinylated at a specific lysine residue (K1299) by the 
E3 ubiquitin ligase complex CLR4 potentially inducing a conformational change that favors binding of 
TETs to the DNA (Yu et al., 2013). 
 
 
 
 
                                                                                                                                                       
                                                                                                                                                      An et al, Exp Mol Med. 2017 
Figure  8. Domain structure of TET proteins. TET proteins share similar structure subdivided between N-terminal variable 
region and C-terminal conserved catalytic domain. 
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5.4 5hmC and regulation of gene expression 
Besides serving as demethylation intermediate, 5hmC may carry out additional functions as an 
epigenetic mark with functional roles in the regulation of gene transcription (Cimmino and Aifantis, 
2017). Indeed, as mentioned above, large-scale mapping revealed that the global content of 5hmC in 
different mouse and human cell types varies in a 5mC-independent manner (Nestor et al., 2012). 
Along the same line, confirming the concept that 5hmC and its oxidized forms could have an 
independent function from 5mC, deletion of TET proteins does not always lead to increased levels of 
5mC at specific genomic loci (Huang and Rao, 2014).  
The recent development of enrichment-based and single base-resolution techniques to analyse 
5hmC, provided a more complete picture of its distribution across the mammalian genome, giving 
insights into the possible functional role of 5hmC in transcriptional regulation. For example, in 
murine ES cells data showed that 5hmC levels are low at promoters of highly expressed genes, 
characterized by high CpG density and marked by H3K4me3 (commonly associated with the 
activation of transcription of nearby genes). In comparison, promoters with low-to-intermediate CpG 
density have higher levels of 5hmC (Booth et al., 2012; Wu et al., 2011; Yu et al., 2012).  
Of note, in ES cells high level of 5hmC is observed at promoters characterized by bivalent histone 
marks: H3K27me3 (associated to gene downregulation thorough the formation of heterochromatin 
regions) and H3K4me3. These promoters correspond to genes transcriptionally inactive in ES cells but 
then activated upon differentiation. The same correlation with bivalent domains is not true for 5mC 
(Fouse et al., 2008). This evidence suggests the hypothesis of a unique functional contribution of 
5hmC: it could be involved in the maintenance of an inactive chromatin configuration, but poised to 
rapid activation in response to the appropriate signals (Pastor et al., 2011).  
Moreover 5hmC showed a deposition in gene bodies from TSSs to transcription termination sites 
(TTSs), emphasizing its potential correlation with transcriptional elongation (Sun et al., 2015). 5hmC 
is also enriched at distal regulatory elements such as enhancers, which are often regions of low-to-
intermediate CpG density with reduced levels of DNA methylation respect to neighbouring regions 
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(Stadler et al., 2011). Specifically, single-base resolution mapping highlighted that 5hmC is strongly 
enriched at flanking regions of TF binding sites, but relatively low at the precise site of binding, 
further emphasizing that 5hmC may have a regulatory role in transcriptional activation (Yu et al., 
2012). However, due to the absence of data on the binding of TF to enhancers in TET-deficient cells, 
there are still open questions regarding the precise mechanism involving 5hmC and TET enzymes as 
possible transcriptional regulators. One possibility could be that 5hmC ‘opens’ the chromatin 
structure allowing the binding of TFs, or that TFs recruit TET enzymes catalyzing the formation of 
5hmC at these regulatory regions. On the other hand, the depletion of 5hmC at the precise TF 
binding site could be explained by a process of TET-assisted demethylation, or by a physical blockage 
by TFs of the access of TET enzymes in this region. In agreement with this latter possibility, in 
differentiating ES cells (Sérandour et al., 2012), 5hmC levels strongly increase at activated enhancers 
marked also by acetylation of H3K27, a common mark of active enhancers. Consistent with these 
results, mouse ES cells lacking a functional TDG pathway (thereby with an impaired DNA 
demethylation machinery) showed an accumulation of 5fC and 5caC at enhancer regions, further 
corroborating the fact that active demethylation processes take place at this regulatory region (Shen 
et al., 2013). Along the same line, recent work showed that in ES cells TET1 recruits the SALL4A TF at 
enhancer regions and, this process allows the subsequent recruitment of TET2, which mediates 
further oxidation of 5hmC present at SALL4A-bound sites (Xiong et al., 2016). These results suggest 
that TET1 and TET2 cooperate and are coordinated by SALL4A that in turn recognize 5hmC. Moreover 
SALL4A was shown to be a genomic region-specific regulator of 5hmC deposition (Xiong et al., 2016). 
The use of quantitative mass spectrometry-based proteomics techniques further supports the 
growing evidence of 5hmC as a stable epigenetic mark for the recruitment of chromatin or 
transcription regulators. Indeed it was shown that specific proteins bind selectively to 5hmC in ES 
cells, neural progenitor cells and mouse adult brain (Spruijt et al., 2013). These proteins include the 
neural progenitor cell-specific protein UHRF2, TF such as zinc-fingers and homeoboxes protein 1 
(ZHX1), ZHX2 and THAP domain-containing protein 11 (THAP11), and several uncharacterized 
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proteins (Spruijt et al., 2013). In addition, two methyl-binding proteins, methyl-CpG-binding protein 2 
(MeCP2) and methyl-CpG-binding domain protein 4 (MBD4), were shown to recognize and bind 
5hmC (Mellén et al., 2012; Otani et al., 2013). In particular, the work of Mellen et al. identified a role 
for MeCP2 in the regulation of chromatin structure, although a mechanism by which MeCP2 binding 
to 5hmC could regulate chromatin accessibility remains to be determined.  
Overall these findings strongly corroborate the potential involvement of TET proteins and 5hmC in 
the regulation of gene expression, but further investigation is needed to elucidate how proteins that 
bind 5hmC contribute to gene regulation, and how catalytic activity of TET enzymes is influenced by 
the interaction with other proteins.  
Regarding the activity of TET enzymes, there is increasing evidence showing that these proteins may 
also work independently of their catalytic activity by repelling or recruiting other factors. For 
instance, TET1 can be involved in transcriptional regulation through its interaction with the SIN3A 
histone deacetylase complex (Williams et al., 2011); similarly TET2 can regulate transcription by 
recruiting histone deacetylase 2 (HDAC2) (Zhang et al., 2015). Along the same line, it was shown that 
TET proteins in ES cells can modulate transcription in a catalytic-activity-independent manner by 
recruiting O-linked N-acetylglucosamine transferase (OGT) (Vella et al., 2013).  
Further evidence supporting the hypothesis of a catalytic-activity independent function of TET 
proteins comes from data demonstrating that mutated forms of TET proteins can have biological 
function although catalytically inactive. For example, in mouse hippocampus, overexpression of a 
catalytically inactive form of TET1 affects memory in a way similar to the wild-type TET1 (Kaas et al., 
2013); during the inflammation resolution of innate myeloid cells, catalytically inactive TET2 recruits 
HDAC2 and in so doing it represses IL-6 transcription (Zhang et al., 2015); and in HEK 293T cells 
overexpression of wild-type TET1 and its mutated form showed highly similar transcriptional changes 
(Jin et al., 2014). Finally, in mast cells, hyperproliferation resulting from TET2 deletion could be 
rescued by a catalytically dead mutant (Montagner et al., 2016).                                                                                                                                                 
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Overall these data strongly suggest a role of TET enzymes and 5hmC in the regulation of gene 
expression, with multiple levels of regulation contributing to the final definition of specific gene 
expression patterns. Indeed, transcriptional activation or repression can be accomplished depending 
on the specific genomic region, and also on the activity of interacting factors able to ‘read’ 5hmC 
modification, or to influence TET enzymes catalytic activity. 
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6. Epigenetics in T lymphocytes 
Following antigenic stimulation, antigen-inexperienced naive T cells proliferate and differentiate into 
an array of effector and memory subsets, with responses specific for the elimination of the pathogen 
being recognized. The controlled activity of TFs and epigenetic mechanisms define the specific 
transcriptome of each subset (Bevington et al., 2016). Indeed, several genes controlling immune 
functions are known to be regulated by epigenetic modifications (Leoni et al., 2015a). In the next 
section I will describe the impact of DNA methylation and DNA hydroxymethylation in T lymphocytes 
development, differentiation and acquisition of effector functions. 
 
6.1 Role of DNA methylation in immune‐regulation 
Mouse models lacking DNMT enzymes showed that DNA methylation can be dynamically modulated 
during T cell development and lineage-specific gene expression programs. Indeed, the generation of 
mice lacking Dnmt1 at sequential stages of T cell development, showed for example that double-
negative thymocytes have an impaired activation-induced proliferation; moreover naive T cells in the 
periphery have increased cytokines expression. This work was the first demonstration that Dnmt1 
and DNA methylation are required for the proper expression of specific genes important to define 
lineage and dictate function in T cells (Lee et al., 2001). In subsequent work it was also shown that in 
the absence of DNMT1, murine CD4+ and CD8+ T lymphocytes are not able to silence properly the Il4 
locus, resulting in increased and dysregulated production of TH2-type cytokine (Makar and Wilson, 
2004; Makar et al., 2003). Moreover, T cell activation in the presence of specific cytokines promoting 
TH2 polarization, reduced DNMT1 recruitment to the Il4-Il13 locus, eventually leading to enhanced 
gene expression (Makar et al., 2003). These results further underline the central role of DNMT1 and 
DNA methylation for proper cytokine expression and lineage commitment. Dysregulated and 
promiscuous cytokine expression was observed even in the absence of DNMT3A (but not DNMT3B); 
indeed murine CD4+ T lymphocytes showed increased and simultaneous expression of IFN-γ and IL-4 
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after expansion under non-polarizing conditions. In details, DNMT3A was shown to be required for 
the establishment of a normal pattern of DNA methylation at the ifng locus under TH2 polarizing 
conditions, but it becomes dispensable for directing the appropriate expression of IFN-γ and IL-4 in 
already TH1 and TH2-polarized cells; however TH2 cells lacking Dnmt3a showed increased expression 
of IFN-γ under TH1 polarizing conditions (Gamper et al., 2009).  
These results indicate that DNMT3A has a critical role in stabilizing T cell gene expression through the 
methylation of selective targets. More recently, methylome analysis of murine CD4+ T cells 
investigated changes in DNA methylation patterns during the process of T cell differentiation, and it 
emphasized changes in chromatin architecture concomitant with the acquisition of effector/memory 
phenotype upon naive T cell stimulation. In addition, methylation profiles were different between 
memory T cell subsets, indicating a link between the status of T cell methylation and T cell 
differentiation (Hashimoto et al., 2013). A global DNA methylation remodeling accompanying the 
acquisition of effector functions and repression of the naive cell state was observed also in murine 
CD8+ T lymphocytes (Scharer et al., 2013).  
These observations were confirmed also in human; indeed genome-wide characterization of 
epigenetic changes in human CD4+ T lymphocytes showed differential methylation between memory 
and naive cells, connected to differential gene expression following activation. In particular, memory 
cells were characterized by a progressive global loss of DNA methylation correlating with activation-
induced gene expression compared to naive cells (Durek et al., 2016; Komori et al., 2015).  
The central role played by DNA methylation in the proper regulation of immune responses was 
observed also in Treg cells, characterized by the expression of the TF Foxp3. Mutations in the Foxp3 
gene cause the scurfy phenotype in mice and IPEX (immune dysfunction, polyendocrinopathy, X-
linked) syndrome in humans (Lal and Bromberg, 2009). The maintenance of Tregs phenotypic 
stability is strictly connected with a stable Foxp3 expression. There are different mechanisms to 
preserve Treg cell identity (Feng et al., 2014). In particular, a stable Foxp3 expression was associated 
with selective demethylation of a regulatory region within the Foxp3 locus called TSDR (Treg-specific 
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demethylated region); this work demonstrated that epigenetic imprinting of this region is important 
for the establishment of a stable Treg lineage (Polansky et al., 2008). However, DNA methylation 
appears to have a complex role in regulating Treg stability and function. Expression of DNMT1 (but 
not DNMT3A) was shown to be necessary for Treg development and function; in fact, deletion of 
DNMT1 did not affect methylation patterns within Foxp3, but decreased global DNA methylation 
altering the Treg expression of many pro-inflammatory genes, and mice with conditional deletion of 
DNMT1 in Tregs died because of lethal autoimmunity (Wang et al., 2013).  
 
6.2 Role of DNA hydroxymethylation in immune‐regulation 
Before the discovery of TET proteins, DNA demethylation was thought to occur exclusively through a 
passive process connected with cell proliferation, where DNMT1 fails to methylate the nascent DNA 
strand during the S phase of the cell cycle. But growing evidences suggested a possible role for DNA 
demethylation in immune genes transcriptional regulation, mediated by an active enzymatic 
mechanism. Indeed, upon activation of murine CD4+ T lymphocytes a rapid and specific 
demethylation of the Il2 promoter was observed, in absence of DNA replication and causally 
affecting Il2 gene transcription. This work suggested that the T cells possessed an active enzymatic 
mechanism for demethylation involved in the regulation of immune gene expression (Bruniquel and 
Schwartz, 2003). Similarly, modifications in the level of DNA methylation were observed at the Ifng 
locus in memory CD8+ T lymphocytes; the Ifng gene promoter was partially methylated at resting 
state, but became rapidly demethylated upon antigenic stimulation in a proliferation-independent 
manner, inferring again a demethylase activity (Kersh et al., 2006).  
The discovery of the TET enzymes (Tahiliani et al., 2009) provided a new perspective on several 
potential mechanisms by which they might mediate DNA demethylation, suggesting a possible role of 
DNA hydroxymethylation and TET proteins in the regulation of T cell development and 
differentiation. Genome-wide mapping of 5hmC distribution in murine thymocytes and peripheral T 
      Chapter 6 – Epigenetics in T lymphocytes 
 
 
62 
cells at several developmental stages, provided a characterization of 5hmC dynamics during thymic 
development and peripheral TH1 and TH2 differentiation. One remarkable finding was the tight 
connection, observed in differentiating T cells, between gain of gene expression and gain of 5hmC; 
indeed intragenic 5hmC levels were high in gene bodies of highly expressed genes, and this was 
correlated with marks of active transcription (H3K4me3, H3K27me3) (Zhou et al., 2011).  
In parallel, by investigating 5hmC dynamics at different stages of T cell development, it was found 
that 5hmC is enriched in active thymus-specific enhancers during the transition from double negative 
thymocytes to single positive CD4 and CD8, again emphasizing the correlation with gene expression 
(Tsagaratou et al., 2014). Together, these data provided valuable insights into the potential biological 
roles of 5hmC and set the bases for the investigation of 5hmC function in immune-regulation. 
However, germline deletion of mouse Tet2 led to largely normal B and T lymphocyte development 
(Tsagaratou et al., 2017), although Tet2 deletion in early lymphoid progenitors showed a partial 
reduction of IFN-γ and IL-17 expression in TH1 and TH17 cells respectively (Ichiyama et al., 2015), 
suggesting that TET2 promotes DNA demethylation and activation of cytokine gene expression in T 
cells. The important discoveries made on the role of TET-5hmC during differentiation of mammalian 
CD4+ T cells obtained from mouse models, were confirmed also in humans, revealing the importance 
of DNA demethylation in terms of 5hmC in human CD4+ T cell differentiation. Specifically, Nestor et 
al. generated genome-wide 5hmC and gene expression profiles during in vitro differentiation of CD4+ 
naive T lymphocytes into the TH1 and TH2 subsets. They showed a global reduction in genomic 5hmC 
during both activation and differentiation of CD4+ T cells, associated with a modest gain of 5hmC at 
specific genomic regions involved in T cell activation. These findings were confirmed in CD4+ memory 
T cells ex vivo, suggesting that early remodeling events persists in long-term differentiated cells 
(Nestor et al., 2016). These results support the concept of an important role of 5hmC in human gene 
regulation and lineage commitment. However, 5hmC dynamics upon T cell activation need to be 
further characterized, in particular in terms of what is the relative contribution of passive and active 
mechanisms of demethylation in regulating T cell activation, and also which is the specific role of 
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5hmC in gene transcriptional activation. Further studies will provide a more complete understanding 
about the role of DNA hydroxymethylation in human immune-regulation.  
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7. Aim and overview of the study 
Efficient immune responses orchestrated by CD4+ T lymphocytes require both lineage commitment 
and phenotypic flexibility, allowing the development of responses tailored to invading pathogens. 
Stability in the expression of subset-specific genes must be reconciled with mechanisms enabling 
plastic phenotypic changes in response to environmental cues. In mammals, the 5mC modification in 
the genomic DNA contributes to the dynamic control of gene expression, where the methyl mark 
erasure is required for the activation of developmental programs. DNA demethylation can occur 
either through passive dilution during DNA replication, or through active mechanisms mediated by 
TET enzymes that catalyze oxidation of 5mC to 5hmC, which can be further oxidized. Of note, 5hmC 
is a stable mark that contributes to the regulation of activation and differentiation of human CD4+ T 
cells, however 5hmC dynamics upon T cell activation need to be further characterized. In particular, 
although the basic mechanistic aspects of passive and active demethylation are well described, it is 
still unclear which is their relative contribution in regulating T cell activation and effector functions. 
Therefore, the overall aim of this thesis is to investigate the contribution of active and passive 
mechanisms of 5mC and 5hmC removal in primary human T lymphocytes, as well as to characterize 
changes in 5mC and 5hmC both genome‐wide and at specific loci relevant for T cell functions.  
 
The studies I performed to achieve this aim are described in a manuscript addressing the role of 
passive and active DNA demethylation in the functional regulation of human T lymphocytes 
(Manuscript 1). This manuscript represents the largest part of my PhD studies and I performed the 
majority of the experiments described.  
I also contributed to a review article describing the role of epigenetics modifications in T lymphocytes 
(Manuscript 2). 
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My specific contributions to each manuscript are as follows: 
Manuscript 1 
The contribution of active and passive mechanisms of 5mC and 5hmC removal in human T 
lymphocytes is differentiation‐ and activation‐dependent 
L. Vincenzetti, C. Leoni, M.Chirichella, I. Kwee, S.Monticelli 
This is an author produced version of the manuscript reviewed by Cell Reports. 
The expression of immune-related genes is transcriptionally regulated by 5mC and 5hmC in the 
genomic DNA. In this work, in order to understand the role of such modifications in modulating 
human T lymphocyte activation and functions, we started by measuring the levels of 5mC and 5hmC 
in different subsets of T lymphocytes. Resting naive T cells showed higher levels of 5hmC and 5mC 
compared to their memory counterparts. However, upon activation, all subsets displayed a 
significant decrease in the overall levels of genomic 5hmC, although the strongest effect was 
observed in naive T cells, pointing towards a role for 5hmC in the activation of antigen-inexperienced 
naive T lymphocytes. To further investigate whether genomic 5hmC and 5mC can indeed influence 
the acquisition of effector functions by T cells, we treated T cells with vitamin C (to enhance DNA 
demethylation) or decitabine (to block DNA methylation). Both treatments increased the ability of 
the cells to produce effector cytokines such as IFN-γ, suggesting that DNA methylation-related 
processes are required for the efficient differentiation of T cells to effector and memory subsets. The 
reduced levels of genomic 5mC and 5hmC observed upon T cell activation could be due to either 
enzymatic processes of active DNA demethylation, or to passive dilution due to DNA replication 
during cell proliferation. To understand the relative contribution of active and passive DNA 
demethylation during T cell activation, we performed experiments aimed at separating T cell 
activation from proliferation. We found that the observed reduction in 5hmC do not strictly require 
TCR engagement, and it is primarily due to passive dilution, although active demethylation processes 
are also present during the early phase of activation of naive, but not memory, T cells. Active 
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processes of demethylation appeared to be critical in quiescent naive T lymphocytes for the 
maintenance of regulatory regions poised for rapid responses to physiological stimuli. Finally, 
because DNA demethylation correlated with the acquisition of effector functions, we further 
investigated changes in 5mC and 5hmC both genome-wide and at specific loci relevant for T cell 
functions. From the data obtained, we hypothesized a model in which in the absence of cell 
proliferation, 5hmC enables the expression of housekeeping and early response genes, presumably 
by counteracting DNA methylation at these regions. Conversely, a small subset of effector genes 
acquired 5hmC upon activation and proliferation, and these changes correlated with gene 
expression.  
This work constituted the major focus of my PhD and therefore I performed the vast majority of the 
experiments required for this study, apart from: the generation of genome-scale DNA methylation 
profiles by RRBS (reduced representation bisulfite sequencing), which was outsourced at Diagenode, 
the MeDIP (methylated DNA immunoprecipitation) and hMeDIP (hydroxymethylated DNA 
immunoprecipitation) experiments, and the analysis of already published datasets in human naive T 
cells. 
Manuscript 2 
Epigenetics of T lymphocytes in health and disease 
C. Leoni, L. Vincenzetti, S. Emming, S. Monticelli – in Swiss Med Wkly (2015) 145:w14191. 
In this manuscript we reviewed the published literature regarding the role of DNA methylation and 
hydroxymethylation dynamics in the regulation of gene expression, and we mainly focused on their 
role in coordinating functions of T lymphocytes during normal immune responses, as well as in 
autoimmune disease. I contributed to the discussion of studies describing DNA methylation dynamics 
in the modulation of cytokine production upon T cell activation, underlining in particular the possible 
role of active DNA demethylation in T cells differentiation and effector responses. 
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8. Discussion 
During their development and until terminal differentiation, T lymphocytes make sequential cell fate 
choices each one characterized by a specific gene expression program, and once initiated, these 
programs must be faithfully propagated in an heritable manner from parental cells to their progeny. 
But, at the same time, stability in the expression of specific genes must be reconciled with 
mechanisms enabling plastic phenotypic changes in response to environmental cues. Epigenetic 
mechanisms, including DNA methylation and modifications in chromatin structure, allow T cells to 
tune the threshold of specific gene expression and thereby help to determine T cell fate and 
function. Cell cycle progression is considered to be the key mechanism to reprogram and relieve 
epigenetic repression during differentiation. The work presented in this thesis shows the existence of 
an active process of 5hmC removal that is operating specifically in naive T cells prior to cell-cycle 
entry, while passive, replication-dependent dilution of the modified cytosines is at work in memory T 
lymphocytes. Consequently, we hypothesized that the active removal of cytosine modifications 
contributes significantly to the first activation of naive T lymphocytes, while on the other hand 
replication-dependent dilution is the driving force leading to 5hmC reduction in highly proliferative 
already differentiated cells. 
The data presented in this work could provide an answer to the following question: how are naive T 
lymphocytes, as slowly or rarely proliferating cells, able to remove repressive DNA methylation and 
become amenable of transcriptional activation and poised for rapid response to stimuli? 
Previous studies of 5hmC during differentiation of mouse CD4+ T cells reported a global loss of 5hmC 
in differentiated TH cell subsets (Ichiyama et al., 2015; Tsagaratou et al., 2014). These findings were 
confirmed also in human, showing a global reduction in genomic 5hmC during both activation and 
differentiation of CD4+ T lymphocytes (Nestor et al., 2016). However, 5hmC dynamics need to be 
further characterized, in particular in term of what is the relative contribution of passive and active 
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mechanisms of DNA demethylation in the significant decrease of genomic 5hmC observed upon T cell 
activation and differentiation, and if there are possible differences between naive and memory T 
lymphocytes. In this work, first of all we found that unstimulated naive T cells maintained higher 
levels of 5hmC compared to those of all other antigen-experienced T lymphocytes, suggesting a role 
in the initial activation of naive but not memory T cells.  
Then, we optimized systems to uncouple T cell activation from proliferation by analyzing early time 
points of T cell activation prior to cell cycle progression, and by stimulating cells in the presence or 
absence of cell cycle inhibitors. These experimental approaches gave a full characterization about the 
dynamics of passive and active mechanisms of DNA demethylation upon T cell activation. In 
particular they were consistent with the idea of a predominant role for proliferation-dependent 
dilution of 5hmC upon activation of naive T lymphocytes. In these cells, an active mechanism of 
removal of the 5hmC mark may be at play in a narrow window of time prior to cell cycle entry, 
contributing significantly to their activation. Our observations are consistent with studies showing 
that 5hmC-mediated processes may be important in rarely dividing cells like post-mitotic neurons in 
mammalian brain. In particular, active DNA demethylation has been shown to occur both in cultured 
neurons (Martinowich et al., 2003) and in various brain regions in vivo (Ma et al., 2009), indicating 
important roles for DNA demethylation dynamics in regulating neuronal plasticity, similarly to our 
findings in non-proliferating naive T cells. 
But more specifically, which is the primary role of 5hmC in gene transcriptional activation in T 
lymphocytes, especially in naive T cells? 
One possibility is that the presence of 5hmC is required to counteract deleterious DNA methylation 
to regions that are not actively transcribed in resting lymphocytes, but require fast activation upon 
antigen recognition. In line with this, we found that regulatory regions of several early response 
genes (genes that can be rapidly transcribed upon activation of resting cells and in the absence of 
proliferation), were characterized by an enrichment in levels of 5hmC. This is also in agreement with 
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recent findings showing that the activity of TET proteins is important in ES cells to preserve 
promoters from de novo methylation to ensure robust lineage-specific transcription upon 
differentiation; this mechanism was thought to facilitate rapid changes of methylation state to 
activate transcription in a locus-specific manner (Verma et al., 2018). Similarly, TET1 was shown to be 
not directly involved in initiation of global DNA demethylation during epigenetic reprogramming in 
gonadal primordial germ cells, but it was found to have a critical role in preventing the spreading of 
DNA methylation (Hill et al., 2018). Consequently, in T lymphocytes, the main role of 5hmC might be 
to counteract DNA methylation in particular in resting, non-proliferating naive T cells, which cannot 
take advantage of passive (cell-cycle dependent) mechanism of dilution to eliminate wrongful 
methylation.  
Another possibility explaining the role of 5hmC in maintaining naive T cells in a state amenable of 
transcriptional activation comes from the following question: what triggers the opening of chromatin 
at enhancers to overcome a nucleosomal barrier and start regulatory events? Different hypothesis 
include the involvement of pioneer TFs that can recruit chromatin modifiers, or they can directly bind 
to nucleosomal DNA making it competent for the occupancy of other TFs through the repositioning 
of nucleosomes, or they can protect the enhancer region from DNA methylation (Calo and Wysocka, 
2013; Zaret and Carroll, 2011). Moreover the histone modification H3K4me1 was found to be 
enriched at the level of enhancers (Heintzman et al., 2007), and it was suggested not to be tightly 
linked to enhancer activity, but to favor it by facilitating nucleosomal mobility and/or binding of 
pioneer TFs. Interestingly, 5hmC enrichment at enhancers was shown to be characterized by the high 
concordance with H3K4me1 (Yu et al., 2012), corroborating the idea that 5hmC could participate in 
the multiple levels of regulation of transcriptional activation. In particular, 5hmC may be part of 
enhancer activation process in its own right by counteracting transcriptionally restrictive chromatin 
states or by recruiting yet to be identified effector molecules (Calo and Wysocka, 2013). Considering 
these observations, in the context of this thesis, 5hmC may have a critical role at specific enhancers 
in order to create a ‘window of time’ for enhancer demethylation upon T cell activation, allowing 
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even quiescent naive T cells to be poised for transcriptional activation. Supporting this possibility, our 
analysis of available ATAC-seq datasets of human naive T cells (Mumbach et al., 2017) revealed that 
ATAC-accessible regions were indeed enriched of 5hmC, highlighting the possible interaction 
between 5hmC, TF binding site accessibility and nucleosome positioning in regulating transcriptional 
activation. Finally, the fate of 5hmC itself needs to be further explored in the context of T cell 
terminal differentiation. We found that once the cells overcame their activation threshold and 
entered the cell cycle, 5hmC modification was then lost by passive dilution. Our hypothesis is that 
once T lymphocytes differentiate, their phenotype may become stabilized by other mechanisms 
(such as histone modifications at regulatory regions) and demethylation-dependent mechanisms 
become in turn relatively less relevant; accordingly, the forced expression of TET enzymes in 
activated and proliferating T cells revealed only a modest effect on gene expression (Nestor et al., 
2016).  
Altogether, the work of this PhD thesis supports a model in which the 5hmc mark may be necessary 
to maintain enhancer accessibility in resting T lymphocytes, hence inhibiting DNA methylation of 
regions that must retain a poised state for rapid response upon encounter with an antigen. 
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Abstract 
In mammals, the 5’-methylcytosine (5mC) modification in the genomic DNA contributes to the 
dynamic control of gene expression. 5mC erasure is required for the activation of developmental 
programs and occurs either by passive dilution through DNA replication, or by enzymatic oxidation 
of the methyl mark to 5-hydroxymethylcytosine (5hmC), which can persist as such or undergo further 
oxidation and enzymatic removal. The relative contribution of each mechanism to epigenetic control 
in dynamic biological systems still remains a compelling question. To explore this critical issue, we 
used primary human T lymphocytes, in which two cellular states can be clearly identified, namely 
quiescent naïve T cells, which are slowly or rarely proliferating, and rapidly proliferating activated T 
cells. We found that active mechanisms of methylation removal were selectively at work in naïve T 
cells, while memory T lymphocytes entirely relied on passive, replication-dependent dilution, 
suggesting that proliferative capacity influences the choice of the preferential demethylation 
mechanism. Active processes of demethylation appear to be critical in quiescent naïve T lymphocytes 
for the maintenance of regulatory regions poised for rapid responses to physiological stimuli. 
  
	   -2- 
Introduction 
The methylation of the cytosine base (5mC) in the genomic DNA is essential for mammalian 
development and for cell lineage specification, and is intimately linked with the regulation of gene 
expression (Smith & Meissner, 2013). The bulk genomic methylation patterns are mostly static in 
differentiated cells and tissues, with large stably methylated regions including the inactive X 
chromosome, imprinted genes, pericentromeric repeats and other repeated elements, and transposable 
elements (Bird, 2002). Despite its stability and heritability across cell division, dynamic changes in 
5mC deposition are observed during development and differentiation, and are deemed to be necessary 
for the establishment of stable cell-specific gene expression programs (Wu & Zhang, 2017). Once 
deposited in the genome, 5mC can be removed either through passive dilution during DNA 
replication, which occurs if the methyl mark is not copied on the nascent DNA strand, or through 
active mechanisms mediated by enzymes of the TET (Ten-eleven translocation) family (TET1-3). The 
5mC mark is oxidized by TET proteins to 5-hydroxymethylcytosine (5hmC), which can then undergo 
further oxidation processes (Ito et al, 2010; Tahiliani et al, 2009). 5hmC is however a stable mark that 
can accumulate to significant levels (up to 0.6% of total nucleotides in post-mitotic Purkinje neurons 
(Kriaucionis & Heintz, 2009)), contributing to the regulation of gene expression, possibly by 
recruiting readers of this modification (Wu & Zhang, 2017). Differently from 5mC, 5hmC is enriched 
within the gene bodies of highly transcribed genes and at functional regulatory elements such as 
enhancers (Tsagaratou et al, 2014; Tsagaratou et al, 2017; Wu & Zhang, 2017; Yu et al, 2012a), while 
the vast majority of repetitive elements is enriched with 5mC but not 5hmC (Yu et al, 2012a). The 
5hmC modification can therefore act both as an intermediate of active DNA demethylation and as a 
stable epigenetic mark (Scott-Browne et al, 2017; Wu & Zhang, 2017).  
Whereas basic mechanistic aspects of passive and active DNA demethylation are well characterized, 
it is still unclear what is their relative contribution to the dynamic removal of 5mC and 5hmC in 
evolving biological systems. Therefore, we set out to address this critical issue in a cellular system, 
human T helper (TH) lymphocytes, in which antigen-induced differentiation and activation is 
associated with extensive functional reprogramming and persistent changes in cellular physiology. 
Following the first recognition of a foreign infectious agent, antigen-inexperienced naïve TH cells 
undergo rapid proliferation, and at the same time differentiate into an array of memory and effector 
subsets, with responses tailored towards the specific pathogen being recognized (Kanno et al, 2012). 
At a molecular level, T cell activation and acquisition of effector functions occur through the 
combinatorial action of transcription factors and epigenetic mechanisms to finally establish 
transcriptomes distinctive of each subset (Bevington et al, 2016). 5mC and 5hmC have a variable 
impact on T cell phenotypes, as inferred by mouse models lacking either DNMT or TET enzymes. 
For example, DNA methylation and DNMT enzymes were shown to influence the expression of the 
Il2, Il4 and Ifng cytokine genes in both CD4+ and CD8+ mouse T cells (Bruniquel & Schwartz, 2003; 
Gamper et al, 2009; Kersh et al, 2006; Lee et al, 2001; Makar et al, 2003; Makar & Wilson, 2004; Yu 
et al, 2012b). Genome-wide studies of DNA methylation also highlighted the extent of changes 
accompanying the acquisition of the effector/ memory phenotype upon stimulation of mouse and 
human naïve T cells (Durek et al, 2016; Hashimoto et al, 2013; Komori et al, 2015; Scharer et al, 
2013), with progressive demethylation correlating with differentiation of memory cells. Finally, DNA 
methylation changes and histone modifications occurring during cell cycle progression were shown to 
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control T cell differentiation in the mouse (Bird et al, 1998). As for 5hmC, it is enriched inside the 
body of highly expressed genes in murine T lymphocytes and at active thymus-specific enhancers, 
suggesting a possible role during T cell development and differentiation (Tsagaratou et al, 2014). 
However, germline deletion of mouse Tet2 led to largely normal B and T lymphocyte development 
(Ko et al, 2011; Tsagaratou et al, 2017), although Tet2 deletion in early lymphoid progenitors 
determined a partial reduction of IFN-γ and IL-17 expression by the TH1 and TH17 lymphocyte 
subsets, respectively (Ichiyama et al, 2015). In humans, T cell activation was associated with an 
incompletely characterized global reduction in genomic 5hmC, as well as with a modest gain of 5hmC 
at specific genomic regions associated with T cell activation (Nestor et al, 2016).  
Our data now indicate that naïve T cells rely significantly on an active process of 5hmC removal, 
while active removal of modified cytosines could not be detected in memory lymphocytes, which 
instead used passive, replication-dependent dilution of the modified cytosines. Our data point to the 
notion that the preferential usage of active vs. passive mechanisms of DNA demethylation is 
differentiation- and activation stage-dependent, with active demethylation mechanisms being 
selectively involved in quiescent naïve T cells to maintain regulatory regions poised for rapid 
responses to stimuli. 
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Material and Methods 
Primary human T cell isolation and culture. Blood from healthy donors was obtained from the 
Swiss Blood Donation Center of Basel and Lugano (Switzerland), with informed consent from the 
Swiss Red Cross. Mononuclear cells were separated from peripheral blood using Ficoll-Paque Plus 
(GE Healthcare). CD4+ or CD8+ T lymphocytes were further isolated by positive selection using 
magnetic microbeads (Miltenyi Biotec). Naive and memory T cell subsets were then sorted based on 
the expression of the following surface markers: naïve CD4+ T cells: CD4+CD25–CD45RA+CCR7+; 
memory CD4+ T cells: CD4+CD25–CD45RA–CCR7+/–; TH1 cells: CD4+CD25–CD45RA–CCR6–
CXCR3+; TH2 cells: CD4+CD25–CD45RA–CCR6–CCR4+; TH17 cells: CD4+CD25–CD45RA–
CCR6+CCR4+, TCM (central memory): CD4+CD25–CD45RA–CCR7+; TEM (effector memory): 
CD4+CD25–CD45RA–CCR7–; naïve CD8+ T cells: CD4–CD45RA+CCR7+; memory CD8+ T cells: 
CD4–CD45RA+/–CCR7+/–. Cells were sorted using a FACSAria (BD Biosciences). Human T cells 
were cultured in RPMI-1640 medium supplemented with 1% glutamine, 1% non-essential amino 
acids, 1% sodium pyruvate, penicillin, streptomycin, 50mM β-mercaptoethanol and 5% human serum. 
For in vitro stimulation, T lymphocytes were stimulated using plate-bound anti-CD3 (clone TR66; 5 
µg/ml) and anti-CD28 (1 µg/ml) antibodies. 
T cell proliferation and treatments. To measure proliferation, human T lymphocytes were labeled 
with carboxyfluorescein succinimidyl ester (CFSE, 5 µM, Thermo Fischer Scientific) for 8 min at 
37°C, followed by extensive washing. For experiments of homeostatic proliferation, different subsets 
of CD4+ T lymphocytes were cultured for 6 days in 96-flat bottom microplates in the presence of 
recombinant IL-2 (300 U/ml), IL-6 (25 ng/ml) and TNF-α (25 ng/ml). CD8+ naïve and memory T 
cells were cultured in the presence of IL-7 (25 ng/ml) and IL-15 (25 ng/ml). All recombinant 
cytokines were purchased from Peprotech. For demethylation experiments, CD4+ naïve and memory T 
cells were activated for 5 days in the presence or absence of decitabine (5-aza-2'-deoxycytidine, 
Sigma-Aldrich) used at 1 µM and 5 µM, or were pre-treated for 48h with vitamin C (50 and 100 
µg/ml, Sigma-Aldrich), prior to activation. For experiments using caspase inhibitors, CD4+ naïve T 
lymphocytes were activated for 48 h in the presence of z-LVSR-fmk (inhibitor of MALT1; 40 µM), 
or z-VAD (inhibitor of caspases; 40 µM), kindly provided by Prof. Margot Thome Miazza 
(University of Lausanne). For experiments using cell cycle inhibitors, CD4+ naïve and total memory T 
cells were activated for 3 days in the presence of aphidicolin (1 µg/ml, Sigma-Aldrich) or nocodazole 
(2 µg/ml, Sigma-Aldrich).  
Mouse T cell isolation and culture. Spleens were obtained from 8 weeks-old C57BL/6 male mice 
and homogenized to single cell suspensions. T cells were isolated by negative selection (CD19–
CD11c–CD11b–). CD4+ or CD8+ naïve T cells were then sorted based on the following markers: naïve 
CD4+: CD3+CD4+CD8α–CD62LhighCD44low; naïve CD8+: CD3+CD4–CD8α+CD62LhighCD44low. 
Murine T cells were cultured in RPMI-1640 medium supplemented with 1% glutamine, 1% non-
essential amino acids, 1% sodium pyruvate, penicillin, streptomycin, 50mM β-mercaptoethanol and 
10% fetal bovine serum (FBS). T lymphocytes were activated with plate-bound anti-CD3 (BioLegend, 
clone 145_2c11; 2 µg/ml) and anti-CD28 (BioLegend, clone 37.51; 2 µg/ml) antibodies, with addition 
of 100 U/mL of recombinant IL-2 (Peprotech) after the first 48 hours of stimulation.  
Surface and intracellular stainings. To assess the expression of surface markers of early T cell 
activation, cells were stained with anti-CD25 (Beckman Coulter) and anti-CD69 (BioLegend) 
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antibodies conjugated to different fluorochromes. To measure cytokine expression, cells were 
stimulated for 5 h with phorbol 12-myristate 13-acetate (PMA; 200 nM) and ionomycin (1 µg/mL) in 
the presence of 10 µg/mL brefeldin A (all from Sigma-Aldrich) for the final 2.5 h of culture, followed 
by fixation and permeabilization. Cells were then stained with anti-cytokine antibodies (all from 
BioLegend) conjugated to different fluorochromes, and data were acquired using a Fortessa (BD 
Bioscience) cell analyzer. Flow cytometry data were analyzed with FlowJo. 
Cell lines and transfections. Jurkat T cells were cultured in RPMI-1640 medium supplemented with 
1% glutamine, 1% non-essential amino acids, 1% sodium pyruvate, penicillin, streptomycin, 
kanamycin, 50mM β-mercaptoethanol and 10% FBS. Jurkat cells were transiently transfected with the 
100 µl Neon Transfection System kit (Thermo Fischer Scientific), using 3x106 cells and 30 µg of 
plasmid DNA per condition and the following parameters: 1325 V, 10 ms, 3 pulses. 
Plasmids. Expression plasmids encoding for the full-length human TET1, mouse Tet2 and human 
TET3 were obtained from Addgene (plasmids no. 49792, 41710 and 49446) (Ko et al, 2013; Ko et al, 
2010; Tahiliani et al, 2009). The catalytically inactive form of mTet2, containing the amino acid 
substitutions H1302Y and D1304A, was generated by targeted mutagenesis using the QuickChange II 
XL Site-Directed Mutagenesis Kit (Agilent Technologies). 
Quantitative RT-PCR. Total RNA was extracted using TRI reagent (MRC) and was reverse 
transcribed using the qScript cDNA SuperMix (Quanta Biosciences). Primer sequences for SYBR 
Green qRT-PCR are listed in the Suppl. Table 1. All qPCRs were performed with an ABI 7900HT 
Fast Real-Time PCR System (Applied Biosystems). Data were analyzed using the 2–ΔΔCt method. 
5hmC and 5mC measurements. For dot blot experiments, genomic DNA was isolated using the 
QIAamp DNA Micro Kit (Qiagen) and denatured with 1 M NaOH, 25 mM EDTA at 95°C for 10 min. 
Two-fold dilutions of the denatured DNA were then spotted on a nitrocellulose membrane, from a 
starting amount of 150-500 ng. Following nucleic acid crosslinking (80°C for 2 h), membranes were 
incubated with an anti-5hmC antibody (Active Motif) or an anti-5mC antibody (Epigentek), followed 
by incubation with an HRP-conjugated secondary antibody. Image acquisition was performed with 
the ImageQuant LAS 4000 (GE Healthcare Life Sciences), and quantification was performed using 
the Multi Gauge software. The number of pmol of 5hmC (or 5mC) per µg of genomic DNA in the 
different samples was calculated by comparing the intensity of the signal in the experimental sample 
with that of a standard with known concentration.  
Methylated and hydroxymethylated DNA immunoprecipitation (MeDIP/hMeDIP) and qPCR. 
Genomic DNA from primary naïve and memory T lymphocytes was isolated using the DNeasy Blood 
& Tissue kit (Qiagen), after which 2.5 µg of DNA were sonicated (Bioruptor, Diagenode) to produce 
fragments ranging between 300 and 500 bp. MeDIP was performed using a MeDIP Kit (Zymo 
Research) following manufacturer’s instruction. Briefly, 500 ng of sonicated DNA were denatured for 
5 min at 98°C prior to incubation with 5 µg of anti-5mC antibody for 1 h at 37°C. For hMeDIP, 
sonicated DNA was denatured for 10 min at 95°C, and 1 µg of denatured DNA was incubated 
overnight at 4°C with 1 µg of anti-5hmC rabbit antibody (Active Motif). For both MeDIP and 
hMeDIP, 500 ng of each sample of sonicated DNA were set aside as input. DNA-antibody complexes 
were immunoprecipitated for 3 h at 4°C with 20 µl of Dynabeads Protein G (Invitrogen). Magnetic 
beads were washed 5 times with 1x immunoprecipitation (IP) buffer (10x IP buffer: 100 mM Na‐
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Phosphate pH 7.0, 1.4 M NaCl, 0.5 % Triton X‐100). Beads were then re-suspended in digestion 
buffer (50 mM Tris pH 8.0, 10 mM EDTA, 0.5 % SDS) containing 30 µg of Proteinase K (Ambion) 
and incubated for 3 h at 50°C. Finally, immunoprecipitated DNA was purified using the E.Z.N.A. 
Cycle Pure Kit (VWR-International AG). Quantitative PCR was performed with a 7900HT Fast Real 
Time PCR System (Applied Biosystems) and the percentage of immunoprecipitated 
hydroxymethylated or methylated DNA was calculated as follows: % input = 2(Ct input – Ct IP) x input 
dilution factor x 100 (Leoni et al, 2017). Controls for MeDIP and hMeDIP. To optimize hMeDIP 
efficiency and as a quality control for each immunoprecipitation, a control DNA was produced by 
mixing 1:6 ratio of two otherwise identical PCR products containing either d5hmCTP or dCTP (1ng 
5hmC-PCR : 6 ng C-PCR). Prior to IP, 2 ng of control DNA mix were spiked into every sample and 
after IP, PCR amplification was performed with primers specific for the control DNA. Because an 
EcoRV restriction site was present only in the 5hmC-PCR, further digestion with EcoRV was used to 
determine the specific enrichment of the 5hmC-containing product following IP. Similarly, to assess 
MeDIP efficiency, a control DNA mix containing 1:4 ratio of in vitro methylated and non-methylated 
pUC19 plasmids (MeDIP Kit, Zymo) was added to each sample prior IP. MeDIP efficiency was then 
evaluated by NcoI digestion exactly as described (Leoni et al, 2017).  
Reduced Representation Bisulfite Sequencing (RRBS). Primary naïve and memory T lymphocytes 
were obtained from two independent donors and were either left resting or were stimulated for 3 days 
with anti-CD3 and anti-CD28 antibodies. Genomic DNA was purified using the DNeasy Blood & 
Tissue Kit (Qiagen) and the RRBS experiment itself was outsourced to the Diagenode Premium 
RRBS technology service. The aligned (to the hg19 human reference genome) output data were 
processed using methylKit R package (Akalin et al, 2012). Briefly, Bismark outputs 
coverage2cytosine.txt reports were read by methRead() function.  Bases with coverage below 10 
reads, as well as the one displaying extremely high read coverage (>99.9th percentile of coverage in 
each sample), were filtered out. Samples in each group were pooled to obtain one representative 
methylation profile per sample group and differential methylated CpG dinucleotides were calculated 
through the calculateDiffMeth() function according to Fisher’s exact test. To annotate differential 
methylated CpGs, only CpGs displaying at least 50% of changes in methylation level and having a q-
value (false discovery rate corrected p-value from Fisher’s exact test) ≤ 0.05 were retained. 
Annotation information was retrieved from a BED file containing gene annotation information based 
on hg19 alignment downloaded from UCSC Genome Browser. The RRBS data have been deposited 
in the Gene Expression Omnibus (GEO) database (accession no. GSE113884).  
To review GEO accession GSE113884: 
Go to https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113884 
Enter token gjafwkcwhbglrmb into the box. 
Analysis of hMeDIP-seq data. hMeDIP-seq data were obtained from Nestor et al. (Nestor et al, 
2016). Antonio Lentini (Centre for Personalized Medicine, Linköping, Sweden) kindly provided 
alignments in *.bam format, which were visualized and analyzed with Integrative Genomics Viewer 
software (IGV). Early, late and housekeeping genes were defined by analyzing gene expression raw 
data from Agilent 450k microarray from the same publication (Nestor et al, 2016) using R software 
and Microsoft Excel. To obtain the list of late genes, the following criteria were used: (i) differential 
expression (DE) in TH1 cells between day 0 and day 1 of activation; (ii) DE in TH1 cells between day 
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1 and day 5 of activation; (iii) Log2 DE >1; (iv) increased expression between day 1 and day 5; (v) 
sum of expression values for raw data in all groups > 34. Housekeeping genes were defined as being 
(i) not differentially expressed between the various groups, and (ii) with a minimum expression above 
6.7 in the naïve T cell group. Gene lists were analyzed using DAVID (Huang da et al, 2009a; Huang 
da et al, 2009b) and genes related to T cells and immunity gene ontology categories were selected. 
Finally, the 5hmC levels of the corresponding annotated enhancers for these genes were analyzed. 
Read counts of 5hmC for these enhancers were obtained with Samtools software for Linux. Analysis 
was performed on both the “BB” and “BC” set of samples from CD4+ T cells in vitro polarized 
towards the TH1 or TH2 subsets. Graphs of read counts were made with GraphPad Prism 7.  Enhancers 
and regulatory regions are indicated on the coverage plots either as GeneHancer Identifiers (GH) from 
FANTOM database or as CNSs (Conserved Noncoding Sequences). All references are according to 
the GRCh37/hg19 assembly.  
Statistical analysis. Statistical analysis was performed with Prism software (GraphPad). Data are 
represented as mean ± SEM or SD, and significance was assessed by paired or unpaired Student’s t 
test, two-tailed. 
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Results 
DNA methylation and hydroxymethylation dynamics upon T cell activation. We first determined 
the global changes of genomic 5mC and 5hmC upon activation of primary human T lymphocytes. 
Naïve (TN) and memory (TMEM) cells were separated from the peripheral blood of healthy donors and 
were either left unstimulated or stimulated for 5 days with anti-CD3 and anti-CD28 antibodies. Levels 
of genomic 5mC and 5hmC were then determined by dot blot. Global levels of 5mC were about 1.4-
fold higher in naïve compared to memory T cells, consistent with a role for DNA demethylation 
specifically during cell differentiation (Figure 1a-b) (Durek et al, 2016). Accordingly, in naïve cells, 
levels of 5mC were modestly reduced after 5 days of activation, while memory T cells showed 
negligible changes upon acute stimulation. Compared to 5mC, the dynamic range of changes in 
genomic 5hmC appeared to be much greater, with a global reduction that affected more than 87% of 
the initial 5hmC levels in recently activated naïve cells (Figure 1c). The overall levels of 5hmC were 
on average 4.6-fold higher in resting naïve compared to resting memory or activated T cells, 
effectively separating naïve T cells from all antigen-experienced T lymphocytes (Figure 1c-d). Such 
difference was not justified by the observed differences in 5mC: when calculating the ratio between 
5hmC and 5mC, unstimulated naive cells maintained levels of 5hmC that were 4.3-fold higher 
compared to those of all other T cell subsets (Figure 1e-f).  
The mammalian genome is heavily and stably methylated, especially at stably heterochromatic 
regions such as centromeric repeats, transposons and the inactive X chromosome (Bird, 2002), 
making bulk changes in 5mC difficult to detect, as they are restricted to a much smaller fraction of the 
genome (active genes and enhancers) than that associated with constitutive methylation. Therefore, on 
a global scale, changes in 5hmC provide a more sensitive, albeit indirect, readout of the dynamic 
changes in methylation occurring at gene bodies and regulatory regions (Yu et al, 2012a). Indeed, loss 
of 5hmC indicates either its passive dilution or the further oxidation followed by base excision and 
replacement with an unmethylated cytosine. We therefore analyzed changes in levels of genomic 
5hmC in various conditions of T cell activation. First, similarly to CD4+ T cells, a robust difference 
between naïve and memory cells was observed in human CD8+ T cells, which displayed a strong 
reduction in 5hmC upon activation (Figure 2a). The same phenomenon was also observed in mouse 
CD4+ and CD8+ T cells activated in vitro with anti-CD3 and anti-CD28 antibodies for 3 days (Figure 
2b-c). The high levels of genomic 5hmC characteristic of naïve T cells are likely to ensue during 
thymocyte development in the transition between the double-positive (DP) and single-positive (SP) 
stage (Suppl. Figure 1), although in peripheral cells they may also derive from ongoing processes of 
5mC oxidation.  
Within the human memory compartment, effector memory T lymphocytes (TEM) showed the lowest 
5hmC content, while central memory T cells (TCM) showed intermediate levels between naive and 
TEM cells (Figure 2d). Such trend was inversely correlated with the acquisition of effector functions, 
as shown by the ability of TEM cells to express the highest levels of effector cytokines such as IFN-γ 
and IL-22 (two effector cytokines that are easily detectable in primary T cells not subdivided into 
more specialized subsets) (Figure 2e). Different effector subsets, such as TH1, TH2 and TH17 showed 
low levels of 5hmC that were comparable to those of TEM cells (less than 1 pmol/  µg of genomic 
DNA) (Figure 2f), indicating that the global 5hmC reduction is a general feature of T cell activation 
and differentiation. 
	   -9- 
 
DNA demethylation favors the acquisition of an effector T cell phenotype. Having established 
that levels of 5hmC (and to a lesser extent 5mC) are globally reduced in recently activated naïve T 
cells, we then asked whether the link between DNA demethylation (of which 5hmC represents an 
intermediate) and acquisition of effector functions might be causal. First, we found that the treatment 
of naïve and memory human T lymphocytes with decitabine (DAC), an inhibitor of DNA 
methyltransferases, led to a reduction in global 5mC in proliferating cells that was more prominent in 
recently activated naïve than in memory T cells (Figure 3a-b). The treatment with DAC also led to 
the acquisition of a more effector-like phenotype by activated naïve cells, which showed a significant 
increase in the expression of IFN-γ and IL-22 to levels that were fully comparable to those of memory 
T cells, along with a modest reduction in IL-2 expression (Figure 3c). On memory cells, such effect 
was less apparent, most likely because these cells are already capable of optimal cytokine expression. 
To further clarify the role of DNA demethylation in regulating the expression of effector cytokines, 
we enhanced TET-assisted DNA demethylation by over-expressing TET proteins in Jurkat cells. Our 
initial experiments showed that transfection or transduction of proteins as large as the TET enzymes 
in primary T cells was sufficient to affect T cell activation and even more proliferation, resulting in 
confounding consequences on the final biological effects. We therefore transfected the full-length 
TET proteins in Jurkat T cells, whose proliferation was instead unaffected. The three TET enzymes 
were variably effective at increasing the levels of genomic 5hmC in these cells, with TET2 and TET1 
being the most and the least effective, respectively (Figure 3d). Despite its low efficacy in this system, 
TET1 was expressed by transfected Jurkat cells as expected, it was able to re-activate expression of 
fully methylated, non-replicable reporter plasmids, and it was functional in immunofluorescence 
experiments using 5hmC as readout (Suppl. Figure 2). However, TET1 has already been shown to be 
unable to induce global DNA demethylation, but instead to act as a maintenance DNA demethylase 
that counteracted the spreading of DNA methylation at regulatory regions, potentially explaining its 
limited efficacy in our system (Jin et al, 2014). Notwithstanding such differences among TET proteins, 
increased levels of 5hmC invariably correlated with a modest increase in cytokine expression by 
Jurkat cells (Figure 3e). A catalytically inactive version of TET2 (H1302Y and D1304A) (Ko et al, 
2010; Montagner et al, 2016), was unable to increase either 5hmC levels or cytokine expression 
(Figure 3d-e), suggesting that the observed effects were indeed dependent on the catalytic activity of 
TET enzymes. 
Vitamin C was reported to enhance TET enzymatic activity, by acting as a co-factor that maintains 
the essential atom of iron in the catalytic site in a reduced state (Blaschke et al, 2013; Montagner et al, 
2016; Yin et al, 2013), and to influence differentiation of regulatory T cells in both human and mouse, 
enhancing their suppressive capacity (Yue et al, 2016). To further define the role of DNA 
demethylation-related processes in T cell activation and differentiation, we cultured primary T cells in 
the presence of vitamin C to assess whether its supplementation in the culture medium was sufficient 
to counteract the loss of 5hmC observed upon activation. Treatment of naïve and memory T 
lymphocytes with increasing concentrations of vitamin C led to a corresponding increase in the global 
5hmC levels, as assessed by dot blot (Figure 3f). Increased 5hmC levels correlated with increased 
capacity of memory T cells to produce cytokines, as determined by intracellular staining (Figure 3g). 
Contrary to DAC treatment, increased cytokine expression was observed primarily in memory, but 
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not in naïve T cells, suggesting that vitamin C is sufficient to induce a modest increase in gene 
expression at genomic loci that are already accessible for transcription, but it is insufficient to 
significantly alter the differentiation of naïve T cells. Overall, our results indicate that DNA 
demethylation-related processes are important for the efficient acquisition of effector functions by 
activated T lymphocytes.  
 
Changes in 5hmC do not strictly require TCR engagement and are predominantly linked to T 
cell proliferation. We dissected the relative roles of T cell activation and proliferation in the global 
changes of 5hmC observed upon stimulation of T lymphocytes. To assess whether T cell receptor 
(TCR) signaling was required for such changes in 5hmC, freshly isolated CD4+ naive, TCM and TEM 
cells were cultured in the presence of IL-2, IL-6 and TNF-α to induce cytokine-driven homeostatic 
proliferation (Geginat et al, 2001; Unutmaz et al, 1994) in the absence of TCR engagement. The 
extent of cell proliferation in each of the subsets (as measured by CFSE dilution) reflected their 
activation requirements, as naive cells could barely proliferate in the absence of full antigenic 
stimulation, while TEM cells proliferated efficiently and TCM cells displayed an intermediate phenotype 
(Figure 4a). In each case, the bulk levels of genomic 5hmC inversely correlated with the extent of T 
cell proliferation (Figure 4b-c). A similar result was observed in primary human CD8+ T cells 
undergoing homeostatic proliferation upon culture with IL-7 and IL-15 (Geginat et al, 2003) (Figure 
4d-e), suggesting that T cell proliferation, rather than TCR-dependent activation, is the main driver of 
the observed reduction in genomic 5hmC. Concordant with the fact that TCR signaling is not required 
per se for 5hmC removal, treatment with Z-LVSR, an inhibitor of the MALT-1 paracaspase (Jaworski 
& Thome, 2016), or with Z-VAD, a general caspase inhibitor, did not influence the levels of 5hmC at 
early time points of activation (Figure 4f). The only difference was observed after 48 h of activation, 
when untreated (but not treated) cells entered the cell cycle, leading to a reduction in 5hmC (Figure 
4f, red square).  
To further determine whether the reduction in 5hmC that was observed upon T cell proliferation was 
exclusively linked to passive dilution, we optimized systems to uncouple T cell activation from 
proliferation. First, we defined the changes in levels of genomic 5hmC at early time points of T cell 
activation, prior to cell cycle progression. After stimulation with plate-bound anti-CD3 and anti-CD28 
antibodies, we monitored T cell activation by measuring the surface induction of the early activation 
markers CD25 and CD69 (Figure 5a). After 30 h of activation, cells were uniformly CD69+ (which is 
an earlier marker of activation compared to CD25) and 40-60% of them were already also CD25+, 
indicating effective activation. However, 30 h of stimulation were insufficient for cells to engage in 
cell division, which occurred only after 48 h (Figure 5b). In these experimental conditions, we found 
that 5hmC levels remained stable in the initial stages of activation (until 24 h after activation), and 
decreased rapidly and significantly (by about half) as soon as naïve and memory T cells entered cell 
division (48 h time point); however, we detected a modest but significant decrease in 5hmC in naïve, 
but not memory T cells prior to cell cycle progression, indicating that an active removal of 5hmC may 
be at play specifically in naive T lymphocytes (Figure 5c-d). To further explore this issue, naïve and 
memory T lymphocytes were loaded with CFSE and were then stimulated with plate-bound anti-CD3 
and anti-CD28 antibodies. After 3 days, cells underwent about three cycles of cell division (Figure 
5e). To address whether levels of 5hmC diminished with each cycle, we separated cells contained in 
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each CFSE peak by sorting and we measured the global levels of 5hmC by dot blot. We found that 
memory T cells showed no detectable sign of active 5hmC removal, as the levels of 5hmC dropped 
exactly by half within the first cycle and then became somewhat stabilized at very low levels (Figure 
5e). Naïve T cells showed instead a reduction in 5hmC levels at the first cycle that was higher than 
expected, pointing once again towards a combination of active and passive mechanisms of removal of 
this modified base specifically in these cells.  
To clarify whether indeed an active process of removal of 5hmC may be operating in naïve T cells, 
we stimulated naïve and memory T lymphocytes in the presence or absence of the cell cycle inhibitors 
nocodazole or aphidicolin. Nocodazole interferes with microtubule polymerization, including the 
mitotic spindle, thereby blocking the cells in the G2/M phase, while aphidicolin is a reversible 
inhibitor of the DNA polymerase α resulting in a block in the G1/S phase. After 3 days, untreated 
cells underwent at least three division cycles, while treated cells were for the most part blocked, as 
determined by CFSE dilution (Figure 6a). Despite the block in proliferation, T cells were effectively 
activated, as shown by the induced expression of CD25 (Figure 6a). In memory T cells, inhibition of 
the cell cycle almost completely counteracted the reduction in genomic 5hmC observed in untreated 
cells (Figure 6b-c), pointing towards a passive, proliferation-dependent mechanism of dilution of 
5hmC in activated memory T lymphocytes. Conversely, treated naïve T lymphocytes showed a 
significant loss of genomic 5hmC upon activation, even in the complete absence of proliferation 
(Figure 6b-c). Overall, our data point towards the existence of active mechanisms of removal that are 
operating specifically in naïve T cells prior to cell-cycle entry, while memory T lymphocytes rely 
primarily on mechanisms of proliferation-dependent dilution. 
 
Changes in 5hmC at enhancer regions distinguish early and late response genes. Because DNA 
demethylation correlated with the acquisition of effector functions, we further investigated changes in 
5mC and 5hmC both genome-wide and at specific loci relevant for T cell functions. First, we 
performed reduced representation bisulfite sequencing (RRBS) to generate genome-scale DNA 
methylation profiles. This method directly measures the cytosine methylation state at high CpG-
density sequences such as promoters and a subset of repetitive sequences (Bock et al, 2010; Meissner 
et al, 2008). We found that the majority of differentially methylated regions were observed comparing 
naïve to memory T cells, consistent with previous studies (Durek et al, 2016; Komori et al, 2015), 
while fewer differences were observed upon short-term activation of memory and naïve T 
lymphocytes (Figure 7a and Suppl. Figure 3). The observed differentially methylated regions were 
primarily located within introns and intergenic regions, although hypermethylation at some promoter 
regions was acquired by memory T cells, as compared to naïve cells, regardless of short-term 
stimulation (Figure 7a and Suppl. Figure 3), possibly contributing to T cell differentiation. Indeed, 
analysis of the gene ontology (GO) terms (Chen et al, 2013) associated with the differentially 
methylated promoter regions (defined as -1500bp from the transcription start site (TSS) of the closest 
gene) identified categories reflecting the underlying T cell biology (Figure 7b and Dataset 1). For 
instance, hypo-methylated regions were associated with NF-kB signaling and positive regulation of 
cytokine and chemokine secretion, while hyper-methylated regions were primarily associated to 
regulation of transcription, but also to regulation of TCR signaling and of memory T cell 
differentiation.  
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Because 5hmC is usually enriched at regulatory regions such as enhancers (Tsagaratou et al, 2014; Yu 
et al, 2012a), to assess whether changes in 5hmC could more specifically distinguish patterns of gene 
expression in human T lymphocytes, we analyzed available hMeDIP-seq (hydroxymethylated DNA 
immunoprecipitation and sequencing) data (Nestor et al, 2016) performed on primary human naïve T 
cells and in vitro differentiated TH1 and TH2 subsets. We focused our analysis on two general 
categories of genes, namely i) genes induced in the absence of cell division (including early genes, 
activated within a few hours after T cell activation, such as IL2RA), and ii) late genes, such as IFNG, 
that require multiple cell divisions and DNA demethylation-linked processes before being effectively 
transcribed (Grogan et al, 2001). At all the interrogated regulatory regions of early response genes 
(IL2RA, CD69, ICOS and LTA), we found high levels of 5hmC in resting cells, followed by a general 
reduction consistent with the global decrease in 5hmC observed in activated, proliferating cells 
(Figure 7c and Suppl. Figure 4a). Late genes (IFNG, IL4, CD70, GZMB and CXCL10) showed 
instead comparatively low basal levels of 5hmC in their regulatory regions at resting state, followed 
by an increase during differentiation and proliferation, suggesting a role for 5hmC in facilitating 
transcription of these genes in differentiated T lymphocytes (Figure 7c and Suppl. Figure 5). 
Interestingly, housekeeping genes (genes whose expression did not change in the different conditions 
analyzed) showed either no change of 5hmC (e.g. SDHA) or followed the general reduction in 5hmC 
observed after activation and proliferation (Figure 7c and Suppl. Figure 4b).  
We then confirmed changes in 5mC and 5hmC at the regulatory regions of specific immunologically 
relevant genes by methylated and hydroxymethylated DNA immunoprecipation (MeDIP and 
hMeDIP) followed by qPCR. We selected IL2 and IL2RA as early genes and IFNG as a late gene. We 
observed a variable and generally very modest, if any, reduction in the levels of 5mC at the IL2 and 
IL2RA enhancers (Figure 7d, top). Consistent with previous studies demonstrating a strong 
correlation between hypomethylation of the proximal Infg enhancer and expression of IFN-γ in mouse 
TH1 cells (Schoenborn et al, 2007), we found that this regulatory region, corresponding to the mouse 
CNS-6 (conserved non-coding sequence at -6 kb) was methylated in resting human naïve T cells, and 
underwent demethylation upon activation (Figure 7d, top). The TSS region of IFNG appeared to 
undergo some level of demethylation in activated memory T cells, probably correlating with the high 
levels of transcription of this gene. As for levels of 5hmC, the IL2 and IL2RA enhancers showed a 
general 5hmC reduction following activation, consistent with the global loss of genomic 5hmC 
observed after cell activation and proliferation, while the IFNG proximal enhancer region showed a 
significant 5hmC increase, mirroring the changes in 5mC at this region (Figure 7d, bottom). No 
5hmC changes were detected at the TSS of the IFNG gene. Changes in 5hmC were therefore more 
dynamic than those in 5mC and appeared to have a distinct behavior in early (5hmC reduction) and 
late (5hmC increase) response genes.  
High levels of 5hmC may be critical especially in non-proliferating cells to maintain regulatory 
regions in an accessible state, amenable of transcriptional activation even in quiescent cells. To 
explore this possibility, we analyzed available ATAC-seq (Assay for Transposase-Accessible 
Chromatin and sequencing) datasets in human naïve T cells (Mumbach et al, 2017). Our analysis 
revealed that ATAC-accessible regions were indeed enriched of 5hmC (Figure 7e). Overall, these 
data are consistent with a model in which in the absence of cell proliferation, 5hmC enables the 
expression of housekeeping and early response genes, presumably by counteracting DNA methylation 
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at these regions. Conversely, a small subset of effector genes acquired 5hmC upon activation and 
proliferation, and these changes correlated with gene expression. 
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Discussion 
Cell cycle progression is a key mechanism to relieve epigenetic repression during development and 
differentiation, while terminally differentiated cells acquire a relatively more stable epigenetic 
landscape. Our data now show that active removal of cytosine modifications contributes significantly 
to the first activation of naïve T lymphocytes, while replication-dependent dilution is the driving force 
leading to 5hmC reduction in highly proliferative already differentiated cells.  
If 5hmC is diluted predominantly through DNA replication, why is it important for T cells in the first 
place? One possibility is that the activity of TET proteins is required to counteract the ‘spreading’ of 
DNA methylation to regions that are not actively transcribed in resting lymphocytes, but require fast 
activation upon antigen recognition. Indeed, we found that regulatory regions of several early 
response genes, namely genes that can be rapidly transcribed upon activation of resting cells and in 
the absence of proliferation, were characterized by the presence of 5hmC, suggesting that 5hmC-
dependent processes may be required to counteract deleterious methylation at these regions. The 
5hmC modification at such early response genes was then lost by passive dilution, once the cells 
overcame their activation threshold and entered the cell cycle. Housekeeping genes, that require 
expression even in the absence of proliferation, showed either no changes in 5hmC levels or a 
reduction correlating with the general loss of 5hmC observed in proliferating cells. Finally, activation 
of late effector genes correlated with an increase of 5hmC at their regulatory regions, likely to be 
associated with active transcription and the necessity to establish a stably permissive chromatin 
landscape at these enhancers in differentiated cells. The fact that DNA methylation has the tendency 
to accumulate to transcriptional inactive genes (Bird, 2002), and at enhancers that are not actively 
bound by transcription factors (a process that would be extremely deleterious for genes encoding for 
effector cytokines) was already proposed with the discovery that DNA-binding factors were necessary 
and sufficient to induce local demethylation, and that loss of transcription factor binding was 
conversely sufficient for DNA methylation (Calo & Wysocka, 2013; Stadler et al, 2011). This is also 
in line with recent findings showing that the activity of TET proteins is important to safeguard 
promoters from de novo methylation in embryonic stem cells (ESCs), thereby preserving appropriate 
lineage-specific transcription upon differentiation (Manzo et al, 2017; Verma et al, 2018). Similarly, 
TET1 was shown to prevent the spreading of DNA methylation at CpG islands (Jin et al, 2014), and 
also to be required in germ cells to provide efficient protection from aberrant DNA methylation, 
thereby stabilizing the acquired epigenetic landscape after reprogramming events (Hill et al, 2018).  
In T lymphocytes, the primary role of 5hmC would therefore be to counteract DNA methylation 
especially in resting, non-proliferating naïve T cells, which cannot exploit passive, cell cycle-
dependent mechanisms of dilution as a ‘resetting’ device of wrongful methylation. Such mechanism 
may be especially important for human naïve T lymphocytes: differently from the mouse, in which 
the average lifespan of a naïve T lymphocyte is only 6-10 weeks, individual human naïve T cells can 
persist for 5-10 years without losing significant functionality (den Braber et al, 2012; Kumar et al, 
2018; Thome et al, 2016; van den Broek et al, 2018; Vrisekoop et al, 2008). Similarly to human naïve 
T cells, 5hmC-mediated processes may be crucial in rarely dividing or post-mitotic cells, such as 
neurons, in which replication-dependent dilution cannot occur, and that indeed present exceptionally 
high levels of 5hmC in their genome (Kriaucionis & Heintz, 2009). During mouse brain development, 
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5hmC was shown to be present at poised (yet dormant) loci, in order to facilitate activation at later 
developmental stages (Lister et al, 2013). 
A second related possibility is that the presence of 5hmC may be required at specific enhancers to 
somehow create a ‘window of opportunity’ for enhancer demethylation upon T cell activation, which 
is no longer required once the cells are appropriately activated and can enter proliferation. Indeed, a 
model in which 5hmC could be part of enhancer activation processes somewhat independently of 
5mC was already proposed (Calo & Wysocka, 2013), in which 5hmC may counteract gene silencing 
by opposing chromatin states that would impede transcription, for example through the specific 
recruitment of yet to be identified effector molecules.  
Once T lymphocytes become activated and enter a differentiation pathway towards effector cells, they 
become ‘locked’ in a less plastic memory/ effector state in which demethylation-dependent 
mechanisms are likely to become progressively relatively less relevant. Indeed, many mechanisms 
contribute to the maintenance of the differentiated state, including histone modifications at lineage-
specific enhancer genes and specific expression of master transcription factors essential for lineage 
determination (Kanno et al, 2012; Rothenberg & Zhang, 2012; Wilson et al, 2009). For example, 
permissive histone modifications can be observed at the murine Ifng locus early after T cell activation 
in both TH1 and TH2 polarizing conditions, but a TH1-specific pattern becomes apparent as early as 48 
hours after stimulation (Avni et al, 2002).  However, stable commitment to a single lineage was 
shown to require three-to-four cycles of cell division (Grogan et al, 2001); once this threshold was 
passed, polarized lymphocytes maintained expression of their specific lineage-appropriate cytokines 
even upon removal of polarizing stimuli. The fact that DNA-demethylation processes may become 
less relevant as cell differentiation progresses can be also inferred by the fact that forced expression of 
TET enzymes in already activated and proliferating T lymphocytes revealed only a modest effect on 
gene expression (Nestor et al, 2016).  
Altogether, our data corroborate a model in which 5hmC may be required to maintain enhancer 
accessibility in resting T lymphocytes, thereby counteracting DNA methylation of essential regions 
that must retain a poised state for rapid responses upon encounter with an antigen.  
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Figures and Figure Legends 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Dynamics of 5mC and 5hmC changes in primary human T lymphocytes. (a) Freshly 
isolated naïve and (b) memory CD4+ T lymphocytes were either left resting or were stimulated for 
five days with plate-bound anti-CD3 and anti-CD28 antibodies, followed by genomic DNA extraction 
and measurement of the levels of 5mC and (c-d) 5hmC by dot blot. (e-f) Ratio between genomic 
5hmC and 5mC measured in the previous panels. Each dot represents one individual human donor. 
Mean ± SD. Unpaired t-test. 
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Figure 2. Loss of genomic 5hmC is a general feature of T cell activation. (a) Primary human naïve 
and memory CD8+ T lymphocytes were either left resting or were stimulated for three and five days 
with plate-bound anti-CD3 and anti-CD28 antibodies, followed by measurement of the levels of 
genomic 5hmC. (b) Naïve CD4+ and (c) CD8+ murine spleen T lymphocytes were either left resting 
or were stimulated for three days with plate-bound anti-CD3 and anti-CD28 antibodies, followed by 
genomic DNA extraction and measurement of the levels of 5hmC. Each dot represents one mouse. 
Mean ± SD. Paired t-test. (d) Human naïve, central memory (TCM) and effector memory (TEM) T 
lymphocytes were isolated from peripheral blood and global levels of 5hmC were measured by dot 
blot. One representative blot is shown on the left, while the compiled analysis of several donors is 
shown on the right. Each dot represents one individual donor. Mean ± SD. Paired t-test. (e) Cells were 
isolated as in (d) and the percentage of IFN-γ- and IL-22-producing cells was determined by 
intracellular staining. Each dot represents one donor. Mean ± SD. (f) Individual effector subsets (TH1, 
TH2 and TH17) were freshly isolated from peripheral blood and global levels of 5hmC were measured 
by dot blot. Each dot represents one individual donor. Mean ± SD. 
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Figure 3. DNA demethylation-related processes augment expression of effector cytokines. (a) 
Naïve and memory T cells were separated from peripheral blood and either left untreated or were 
stimulated for five days with plate-bound anti-CD3 and anti-CD28 antibodies, with or without 
addition of decitabine (1 µM or 5 µM). Genomic DNA was purified and global levels of 5mC were 
measured by dot blot. (b) Same as (a), three independent experiments. Mean ± SD. (c) Cells were 
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treated as in (a), except that the expression of the indicated cytokines was measured by intracellular 
staining. Each dot represents one independent experiment. Mean ± SD. Paired t-test. (d) Jurkat T cells 
were transiently transfected with plasmids expressing either full-length mouse Tet2 (wild-type or 
mutated in the catalytic domain), human TET1 or human TET3. 48 h after transfection, genomic 
DNA was isolated and levels of 5hmC were measured by dot blot. Shown is one representative blot of 
at least 3 independent experiments. (e) Cells were treated as in (d), except that they were also 
stimulated with PMA and ionomycin for 3 h to induce cytokine transcription, and total RNA was 
isolated. The expression of the indicated cytokines was measured by qRT-PCR, relative to UBE2D2 
(Ubiquitin-conjugating enzyme E2 D2), used as endogenous control, and relative to cells transfected 
with an empty vector. Each dot represents one independent experiment. Mean ± SEM. Paired t-test. 
(f) Naïve and memory T cells were stimulated for three days in the presence or absence of the 
indicated concentrations of vitamin C. Levels of genomic 5hmC were measured by dot blot. Compiled 
results of three independent experiments are shown on the right. Mean ± SD. Paired t-test, compared 
to untreated cells. (g) Cells were treated exactly as in (f), except that the expression of the indicated 
cytokines was measured by intracellular staining. Shown are the results obtained from cells treated 
with 100 µg/ ml vitamin C. Each dot represents one individual donor. Mean ± SD. Paired t-test. 
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Figure 4. Proliferation, but not TCR engagement, determines the loss of genomic 5hmC. (a) 
Human naïve, TCM and TEM CD4+ T cells were isolated from peripheral blood, loaded with the cell 
tracer CFSE to assess proliferation, and cultured in the presence of IL-2, IL-6 and TNF-α. 
Proliferation was measured after three and six days of culture. (b) Genomic DNA was purified from 
cells as in (a), and levels of 5hmC were measured by dot blot. One representative blot is shown. (c) 
Same as in (b); compiled results of three independent experiments. Mean ± SD. (d) Human naïve and 
memory CD8+ T cells were isolated from peripheral blood and treated as in (a), except that they were 
cultured in presence of IL-7 and IL-15. (e) Dot blot to measure genomic 5hmC of cells treated as in 
(d). (f) Naïve T cells were either left resting or were stimulated with anti-CD3 and anti-CD28 
antibodies, in the presence or absence of 40 µM z-LVSR or z-VAD inhibitors. Genomic DNA was 
collected at the indicated times after stimulation and levels of 5hmC were measured by dot blot. 
Representative of two independent experiments. 
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Figure 5. Active DNA demethylation in naïve, but not memory T lymphocytes. (a) Naïve and 
memory T cells were stimulated with plate-bound anti-CD3 and anti-CD28 antibodies for the 
indicated times. The surface expression of early activation markers (CD25, CD69) was determined at 
each time point by FACS staining. (b) Same as (a), except that cells were loaded with CFSE prior to 
stimulation to measure the extent of cell proliferation at each time point. (c) Same as (a), except that 
genomic DNA was extracted at the indicated time points, and levels of 5hmC were measured by dot 
blot. (d) Compiled results of individual experiments performed as in (c). Each dot represents one 
donor. Mean ± SD. Paired t-test, compared to unstimulated cells. (e) Cells were loaded with CFSE, 
followed by stimulation with plate-bound anti-CD3 and anti-CD28 antibodies. After 3 days, each 
indicated peak was sorted, and levels of 5hmC were measured by dot blot in comparison to 
unstimulated cells. Shown are the results of n=4 independent experiments. Mean ± SD. 
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Figure 6. Inhibition of cell division reduces the loss of 5hmC. (a) Naïve and memory T 
lymphocytes were loaded with CFSE and activated for three days with anti-CD3 and anti-CD28 
antibodies in the presence or absence of the cell cycle inhibitors aphidicolin and nocodazole. The 
extent of cell proliferation was determined by CSFE dilution, while cell activation was evaluated by 
measuring cell size (FSC) and surface expression of CD25. Shown is one representative result for 
naïve T cells. (b) Cells were treated as in (a), and levels of 5hmC in the genomic DNA were measured 
by dot blot. (c) Compiled results of individual experiments performed as in (b). Each dot represents 
one donor. Mean ± SD. Paired t-test, compared to unstimulated cells. 
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Figure 7. Dynamic changes of 5mC and 5hmC at regulatory regions of immune-related genes. 
(a) Left: volcano plot showing the differentially methylated regions observed by RRBS between 
freshly isolated naïve and memory T lymphocytes. Right: the differentially methylated regions shown 
in (a) were analyzed for their genomic location. (b) Selected GO terms significantly associated with 
hypo- or hyper-methylated promoter regions are shown. Differentially methylated regions located in 
	   -31- 
the region upstream of the TSS (0 to -1500bp), with q-value ≤0.2 and with a methylation difference of 
at least 33% were selected for the analysis, which was performed using EnrichR (Chen et al, 2013). 
(c) Levels of 5hmC in differentiated T cells at the indicated loci as assessed by hMeDIP-seq (Nestor 
et al, 2016). (d) MeDIP (top) or hMeDIP (bottom) experiments were performed on naïve and memory 
T cells either resting or stimulated for 5 days with plate-bound anti-CD3 and anti-CD28 antibodies. 
The enrichment for the indicated regulatory regions was measured by qPCR. Each dot represents one 
donor. Mean ± SD. Paired t-test. (e) Correlation of 5hmC signal with ATAC-accessible regions in a 
window of 10 kb in human naïve T lymphocytes. A score matrix of 5hmC score around ATAC peak 
positions was built starting from available data (Mumbach et al, 2017; Nestor et al, 2016). 
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Suppl. Figure 1. Dynamic changes of 5hmC during thymocyte development. Thymi were 
obtained from 8 weeks-old C57BL/6 male mice and homogenized to single cell suspensions. 
Thymocytes were stained with anti-CD4 and anti-CD8 antibodies and separated by sorting in the 
following subsets: double-negative (DN) cells: CD4–CD8α–; double-positive (DP) cells: CD4+CD8α+; 
single-positive (SP) CD4+: CD4+CD8α–; SP CD8+: CD4–CD8α+. Genomic DNA was extracted and 
levels of 5hmC measured by dot blot. Two representative experiments are shown on the left, while the 
compiled results obtained from four independent mice are shown on the right. Mean ± SD. Paired t-
test. 
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Suppl. Figure 2. Expression and functionality of transfected TET1 plasmids. (a) Jurkat cells were 
transiently transfected with a vector expressing full-length human TET1 or the corresponding empty 
vector as control. Total RNA was extracted 48 h after transfection and levels of TET1 were measured 
by qRT-PCR. (b) To determine TET1 functionality, we performed a demethylation reporter assay as 
described (Guo et al., 2011). Briefly, 10 µg of a GFP-expressing plasmid were incubated with 20 
units of M.SssI (CpG methyltransferase, New England BioLabs) and 1600 µM of S-
adenosylmethionine (SAM) for 3 h at 37°C, followed by re-addition of the same amount of M.SssI 
and SAM and incubation for another 3 h. The reaction was stopped by heating at 65°C for 20 min, 
followed by DNA purification. Successful methylation was confirmed by the inability of HpaII (a 
methyl-sensitive restriction enzyme) to digest this plasmid in comparison with the same unmethylated 
plasmid (left panel). The fully methylated GFP-expressing plasmid was used to transfect HEK293 
cells together with a plasmid expressing the wild-type catalytic domain (CD) of TET1 at a 1:6 ratio. 
GFP expression was measured by FACS 96 h after transfection. One representative experiment is 
shown on the right. (c) Exactly as in (b), except that the fully methylated GFP-expressing plasmid was 
co-transfected with different expression constructs for TET1 (full-length (FL) wild-type or mutated in 
the catalytic domain; CD wild-type or mutated). All plasmids were generated using common cloning 
procedures starting from FL WT TET1 (Addgene plasmid no. 49792). CD TET1 corresponds to 
amino acids 1247-2136 of TET1; the mutated form of TET1 contains the catalytic inactivating 
substitutions H1672Y and D1674A, and was generated by targeted mutagenesis using the 
QuickChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies).  (d) TET1 expression and 
functionality from the same plasmids was also assessed by immunofluorescence. HEK293 cells were 
transfected in a 6 wells-plate with 2.5 µg of plasmid using polyethylenimine (PEI) and standard 
protocols. Plasmids were exactly as in (c), with addition of a plasmid expressing the truncated CXXC 
domain of TET1 (lacking the catalytic domain and corresponding to amino acids 1-1412 of TET1). 
For immunofluorescence, transfected cells were fixed with 4% paraformaldehyde for 15 min at RT 
and then permeabilized for 15 min with 0.2% Triton X-100 in PBS. The DNA was denatured by 
treating the slides with 2N HCl for 30 min followed by pH neutralization with 100 mM Tris-HCl 
buffer (pH 8.0) for 10 min. After 1 h of blocking with 1% BSA, cells were stained with rabbit anti-
5hmC antibody (Active Motif) and mouse anti-HA (Santa Cruz Biotechnology), followed by 
incubation with secondary antibodies conjugated with different fluorochromes (Thermo Fisher 
Scientific). For microscope image acquisition, a Nikon Eclipse E800 upright microscope with a 80x 
magnification objective was used. Images were acquired using VisiView software. 
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Suppl. Figure 3. RRBS analysis of primary human T lymphocytes. Volcano plots showing the 
differentially methylated regions observed by RRBS between: i) naïve T cells unstimulated and 
stimulated for 3 days with plate-bound anti-CD3 and anti-CD28 antibodies; ii) memory T cells 
unstimulated and stimulated for 3 days with plate-bound anti-CD3 and anti-CD28 antibodies; iii) 
naïve and memory T lymphocytes stimulated for 3 days with plate-bound anti-CD3 and anti-CD28 
antibodies. In each case the differentially methylated regions (either hyper- or hypo-methylated) were 
analyzed for their genomic location (promoter, exon, intron, intergenic). 
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Suppl. Figure 4. Illustrative snapshots of hMeDIP data (early genes) and analyses of 
supplementary housekeeping genes. (a) Illustrative snapshots of hMeDIP data for early genes 
presented in Figure 4. Red bars represent enhancers and regulatory regions. (b) Analyses of regulatory 
regions of housekeeping genes, supplementary to the one shown in Figure 4. 
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Suppl. Figure 5. Illustrative snapshots of hMeDIP data (late genes). Illustrative snapshots of 
hMeDIP data for early genes presented in Figure 4. Red bars represent enhancers and regulatory 
regions. 
 
 
 	  
  
Supplementary Table 1. SYBR Green qPCR primer sequences. 
 
	  
SYBR Green primers 
Gene name Forward Reverse 
IL2 5’-CCCAGGGACTTAATCAGCAA-3’ 5’-GGTTGCTGTCTCATCAGCAT-3’ 
IFNG 5’-CGAGATGACTTCGAAAAGCTG-3’ 5’-CAGTTCAGCCATCACTTGGA-3’ 
TET1 5’-GAACCATTGGATTCACTCAGC-3’ 5’-GCACACTGGTTAGGTGGAGAG-3’ 
IL2 enhancer 5’-GCTAACTACCACGTGTGTCATACC-3’ 5’-TGCAACACAGTGAGCAATCTC-3’ 
IFNG enhancer 5’-ACTGCAGAATAAGTCACCATCAAGA-3 5’-TGTGTCATGTATAACCATAGCCAGT-3’ 
IFNG TSS 5’-TGGGTGTTGTAGTTAGAGTTTCCTT-3’ 5’-TCAATGTGCTTTGTGAATGAAGAGT-3’ 
IL2RA enhancer 5’-GCAGTTTTCCTCCTGGAAGTT-3’ 5’-TGCAGTCTGAGACCACTCCTT-3’ 
UBE2D2 (endogenous control) 5’-GATCACAGTGGTCTCCAGCA-3’ 5’-CGAGCAATCTCAGGCACTAA-3’ 
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Summary
The risk of developing autoimmune diseases depends on
both genetic and environmental factors, with epigenetic
mechanisms of regulation potentially translating environ-
mental cues into stable modifications in gene expression.
Such stable memory of a functional state has been de-
ciphered into a number of molecular mechanisms that col-
lectively define the epigenetic status of a cell. In recent
years, it has become increasingly clear that epigenetic
modifications are highly dynamic and are able to adapt to
the changing environment, with important impact on the
onset and development of a number of diseases. Here, we
describe some of the epigenetic mechanisms of regulation
of cellular functional states in T lymphocytes, with a partic-
ular focus on DNA methylation. We will also discuss cur-
rent knowledge on the role of epigenetics in autoimmunity
and consider open questions in the field.
Key words: autoimmunity; epigenetics; T lymphocytes;
DNA methylation; microRNAs
DNA methylation and
hydroxymethylation dynamics in the
regulation of gene expression
“Epigenetic” classically described inheritable phenotypes
that are not the result of alterations in the DNA sequence
[1, 2]. Here, however, we will utilise a broader interpret-
ation of such a definition to include all mechanisms that
can provide stability to a given phenotype, including those
that can be important to impart short-term memory of an
environmental signal [3, 4]. Mechanisms providing such
cellular memory of gene expression include histone modi-
fications, as well as regulation mediated by microRNAs
(miRNAs) [3], although we will mainly focus on DNA
methylation dynamics and their role in regulating functions
of T lymphocytes during normal immune responses, as
well as in autoimmunity.
DNA methylation
DNA methylation occurs most commonly at the 5’ position
of the cytosine ring in the context of CpG dinucleotides,
and is mediated by DNA methyltransferase enzymes
(DNMT1, DNMT3a, DNMT3b), which show variable af-
finities for unmethylated and hemimethylated DNA. The
importance of proper DNA methylation throughout mam-
malian development is highlighted by the consequences of
germline deletions of DNMTs: Dnmt1 and Dnmt3b dele-
tions in mice are embryonically lethal, and Dnmt3a-null
mice die perinatally [5, 6].
The relevance of these enzymes can also be inferred from
the fact that they are often found mutated in a variety of
Figure 1
DNA methylation and hydroxymethylation. Cytosine
modifications in DNA have functional consequences on gene
expression. (a) Cytosine can be methylated by DNMT enzymes to
give rise to 5mC, which can be oxidised by TET enzymes to 5hmC
and further products (5fC and 5caC). In an active demethylation
pathway, these products of TET enzymatic activity are likely to be
excised and repaired by the thymine-DNA glycosylase enzyme and
base excision repair mechanisms to regenerate the unmodified
cytosine. Methylated DNA can be recognised by MBD proteins that
can recruit histone modifying complexes (HMTs and HDACs). (b)
DNA methylation occurs at regulatory regions (such as promoters),
but also in gene bodies. DNMT enzymes are responsible for 5mC
deposition, often resulting in the transcriptional repression of the
methylated promoter. TET proteins activity can lead to
demethylation with a potential for transcriptional activation.
5caC = 5-carboxylcytosine; 5fC = 5-formylcytosine; 5hmC =
5-hydroxymethylcytosine; 5mC = 5-methylcytosine; BER = base
excision repair; DNMT = DNA methyltransferase; HDAC = histone
deacetylase; HMT = histone methyltransferase; MBD = methyl-
CpG-binding domain protein; TDG = thymine-DNA glycosylase;
TET = ten-eleven translocation
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diseases. For example, DNMT3a is frequently mutated in
a number of haematological malignancies, and upon trans-
plantation of haematopoietic stem cells lacking DNMT3a,
mice develop a spectrum of malignancies similar to those
seen in patients with mutations in this enzyme, supporting
the crucial role of DNA methylation in disease [7, 8].
Mutations in the gene encoding for DNMT3b are instead
found in patients with ICF (immunodeficiency, centromere
instability and facial anomalies), a recessive autosomal
syndrome, and were shown to lead to reduced DNA
methyltransferase activity [9].
Methylated DNA provides a platform for the binding of
several methyl-CpG-binding domain (MBD) proteins,
which can coordinate downstream processes by recruiting
multiprotein complexes containing histone deacetylases
(HDACs) and histone methyltransferases (HMTs), leading
to chromatin modifications and alterations in gene expres-
sion [5, 10]. However, histone tails can also influence re-
cruitment of DNMTs, which was in fact shown to be in-
dependent of pre-existing DNA methylation [11]. Indeed,
methylation at lysine 4 of histone H3 (H3K4) was shown
to inhibit DNMT3a recruitment [12, 13], and H3K36me3
modulated DNMT3b binding and consequent DNA
methylation specifically to transcribed gene bodies [11].
Importantly, accessibility of selected transcription factors is
also influenced by DNA methylation, since the methylation
status of a binding site can define binding affinity and even
specificity for a given transcription factor [14–17].
Despite such prominent progress in the field and decades
of intensive studies, the precise role of DNA methylation
in regulating gene expression is still not completely un-
derstood, and many concepts about DNA methylation have
had to be reconsidered in recent years. DNA methylation
was classically associated with gene silencing, and this
is indeed usually the case at transposable elements and
gene promoters, but methylation downstream of the tran-
scriptional start site (TSS) usually does not block elonga-
tion [18]. Moreover, DNA methylation was not necessarily
considered of general importance, since model organisms
such as Drosophila melanogaster and Caenorhabditis eleg-
ans show very low or essentially no cytosine methylation
[19]. However, while cytosine methylation represents the
dominant DNA modification in humans, very recent work
showed how organisms with virtually no cytosine methyl-
ation show significant levels of other DNA modifications,
such as N6-methyladenine (6mA), further highlighting a
possible widespread regulatory role of DNA methylation
(reviewed in [20]). Finally, DNA methylation was thought
to be substantially irreversible, other than through passive
mechanisms of dilution, but the recent discovery of path-
ways leading to DNA demethylation have led to a revision
of this idea.
An effort to describe the methylome of up to 17 eukaryotic
genomes was able to show that DNA methylation is highly
conserved in eukaryotes, and that is was likely present in a
common ancestor [19, 21, 22]. Interestingly, methylation of
the gene body was a highly conserved feature across gen-
omes, with exons being usually more methylated than in-
trons and with reduced methylation at both the promoter
region and the 3’ end of genes. While gene expression
was mostly inversely correlated with promoter methyla-
tion, gene body methylation showed a parabolic correlation
with expression: modestly expressed genes are more likely
to be methylated, while both high and low expressers are
the least likely to be methylated [19, 21, 22]. This gener-
ally conserved pattern indicates a role of DNA methylation
in regulating multiple steps of transcription, including ini-
tiation, elongation, termination and even splicing [19, 23].
Indeed, genome-wide studies showed that removal of one
DNMT enzyme leads to both hypo- and hypermethylation
at specific loci, underlying the complexity of the regulation
mediated by DNA-modifying enzymes and further high-
lighting the fact that DNA methylation does not always
equate to gene silencing [24, 25].
Overall, these studies clearly challenged the general dogma
that DNA methylation invariably corresponds to transcrip-
tional silencing, and put forward the idea that the final out-
come on transcriptional regulation relates to the context
and spatial distribution of DNA methylation [10]. There-
fore, DNA methylation appears to be intimately associated
with gene transcription.
Reversal of DNA methylation by hydroxylation
Once thought to be a stable chromatin modification, DNA
methylation is now understood to have a much more dy-
namic nature, as its distribution is influenced by DNA de-
methylation processes, which can occur either passively,
by dilution upon DNA replication at each cell division, or
through an active process initiated by ten-eleven transloca-
tion (TET1-3) enzymes [26] (fig. 1). These enzymes are re-
sponsible for the catalytic conversion of 5-methylcytosine
(5mC) to 5-hydroxymethylcytosine (5hmC) and to further
oxidation products, including 5-formylcytosine (5fC) and
5-carboxylcytosine (5caC) [27, 28]. Similarly to DNMT
enzymes, TET proteins are frequently found mutated in a
number of diseases. Specifically, mutations in the TET2
gene are common in many haematological disorders, and
mice lacking TET2 show expansion of the pool of haema-
topoietic stem cells, with a bias towards myelopoiesis,
which in some cases can turn to myeloproliferative disor-
der [29–33].
Although the biological significance of such oxidation de-
rivatives of 5mC remains to be fully elucidated, several
lines of evidence have determined their importance in tran-
scriptional regulation. Indeed, they are likely to be interme-
diates in processes of DNA demethylation and they modi-
fy the binding patterns of several chromatin regulators and
transcription factors, thereby influencing transcription. A
recent work undertook the challenge of investigating the
identity of a large number of 5mC and 5hmC-interacting
proteins in the mouse, revealing that each cytosine modi-
fication is able to recruit a distinct set of proteins with little
overlap, and also that a large number of proteins prefer-
entially interact with unmethylated cytosines [15]. These
findings further indicate that the role of DNA methylation
is integral to regulation (both positive and negative) of tran-
scription. In general, because many of the methods used to
study DNA methylation in the past could not distinguish
between 5mC and 5hmC [34], it will be interesting to see
how many of the functions attributed in the past to 5mC are
actually dependent (or not) on the presence of 5hmC in the
genome.
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Epigenetic regulation of T cell
functions
T lymphocytes are central to the orchestration of immune
responses to invading pathogens, but their activity has to
be carefully balanced and controlled to avoid tissue dam-
age and pathology. Following antigenic stimulation, naïve
T cells proliferate and differentiate into a number of effect-
or and memory subsets, each characterised by the ability to
produce specific signature cytokines. For example, CD4+
T helper (Th) cells differentiation to the Th1 subset is char-
acterised by the production of high levels of interferon-
gamma (IFNγ). Th2 cells instead mainly produce interleuk-
in (IL)-4 and IL-13, while Th17 cells are characterised by
the expression of IL-17. Th1 and Th17 cells in particu-
lar, and their associated cytokines, have been implicated in
the pathogenesis of autoimmune diseases such as multiple
sclerosis (MS) [35–37].
Several genes controlling immune functions are known to
be regulated by DNA methylation, although our under-
standing of the impact of epigenetic modifications in the
regulation of T cell functions is currently still limited. The
fact that DNA methylation can be dynamically modulated
during T cell responses to an antigen is suggested by a
number of observations. For instance, the Il2, Il4 and Ifng
cytokine genes are known to be regulated by DNA methyl-
ation in T cells [38–40]. In the absence of DNMT1 or
DNMT3a (but not DNMT3b), murine CD4+ T lympho-
cytes were unable to silence properly the Ifng and Il4 loci
under appropriate culture conditions, resulting in increased
and promiscuous cytokine expression [41–43]; even T cells
lacking MBD2 (methyl-CpG-binding domain protein 2), a
reader of methylated DNA, showed a similar phenotype
[44]. T cell activation in Th2-polarising conditions was
shown to reduce substantially recruitment of DNMT1 to
the Il4-Il13 locus in proliferating cells, eventually lead-
ing to reduced DNA methylation of this locus and en-
hanced gene expression [39]. Dysregulated Th2-type cy-
tokine expression in the absence of DNMT1 was observed
even in CD8+ T cells, indicating defective gene silencing
[45]. Moreover, DNMT3a expression was shown in the
Figure 2
DNA methylation dynamics regulate cytokine production in T
lymphocytes. DNA methylation modulates cytokine production
upon T cell activation, and active demethylation processes
(independent of cell replication) have been shown to act at some
cytokine loci. Hypothetically, these processes may involve TET
proteins as an underlying mechanism of demethylation.
5hmC = 5-hydroxymethylcytosine; 5mC = 5.methylcytosine; IFNγ =
interferon-gamma; IL = interleukin; TET = ten-eleven translocation
mouse to be increased by T cell receptor (TCR) engage-
ment. Accordingly, Dnmt3a-null murine T cells showed
hypomethylated cytokine loci and dysregulated cytokine
expression [41]. More recently, genome-wide methylation
studies investigated changes in DNA methylation in effect-
or and memory murine T cells compared with their naïve
counterparts, highlighting the extent of chromatin remod-
elling events accompanying the acquisition of the effector/
memory phenotype upon stimulation of a naïve T cell [46,
47].
Prior to the discovery of TET proteins, models for DNA
demethylation placed emphasis on a passive process due
to a failure of DNMT1 to methylate the newly synthesised
DNA strand during the S phase of the cell cycle. However,
the rapid and DNA replication-independent demethylation
of the Il2 locus that was observed upon activation of CD4+
T cells and that causally affected Il2 gene transcription was
inconsistent with such a model [40]. Along the same line,
dynamic methylation of the Ifng locus was described for
memory CD8+ T lymphocytes: while this locus was par-
tially methylated at resting state, it underwent demethyl-
ation within 5 hours of antigenic stimulation [38]. This
process was independent of DNA replication and cell divi-
sion, and the involvement of a yet unidentified demethylase
activity was proposed [38] (fig. 2). Interestingly, character-
isation of the genome-wide distribution of 5hmC in mouse
CD4+ T cells could not lead to a definitive answer about
the role of 5hmC in T cell differentiation, although it
showed a clear effect of TET2 in modulating effector re-
sponses in some T cell subsets, with reduced IL-10, IFNγ
and IL-17A production in the absence of TET2 [48].
Among the various T cell subsets required to regulate im-
mune responses properly, regulatory T cells (Tregs) are es-
sential to suppress fatal autoimmunity throughout the life-
time of an organism. These cells are characterised by the
expression of the transcription factor Foxp3, which plays a
key role in their differentiation and function. Indeed, muta-
tions or deficiency of the Foxp3 gene lead to the develop-
ment of autoimmune disease, causing the scurfy phenotype
in mice and IPEX (immune dysfunction, polyendocrino-
pathy, X-linked) syndrome in humans [49]. Stable Foxp3
expression is essential to maintain Treg cell identity and
functional integrity, and mechanisms are in place to pre-
serve Treg cell lineage stability [50]. In particular, regu-
latory regions in the Foxp3 locus have to be maintained
free of methylation in order to confer phenotypic stability
to Tregs and, accordingly, inhibition of DNA methylation
using 5-azacytidine or 5-aza-deoxycytidine led to stable
Foxp3 expression [49–51]. By modulating the stability of
the Treg phenotype, DNA methylation could therefore also
have an impact on the onset of autoimmune diseases, and
DNMT inhibitors were proposed as potentially useful tools
to enhance Foxp3 expression in an attempt to limit inflam-
mation [49]. Expression of DNMT1, but not DNMT3a,
was, however, shown to be essential for the appropriate dif-
ferentiation and function of Tregs, and mice with condi-
tional deletion of DNMT1 in Tregs died of lethal autoim-
munity [52]. DNA methylation therefore appears to have a
complex role in regulating Treg stability and function that
may hinder the development of epigenetic-based therapies.
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DNA methylation in autoimmune and
autoinflammatory diseases
Although the aetiology of MS and other autoimmune dis-
eases is still largely unknown, it involves T cell-mediated
processes [35]. Genome-wide association studies (GWAS)
on MS patients have identified several genetic loci associ-
ated with a greater risk of developing the disease. Of these,
the most commonly identified risk locus in MS and other
autoimmune diseases is the major histocompatibility com-
plex (MHC), pointing towards a fundamental role for an-
tigen presentation, but many of the other loci associated
with MS risk are related to immune functions, including
cytokines and cytokine receptors, costimulatory receptors
and signal transduction molecules [53].
Epigenetic mechanisms of regulation of gene expression
may partly explain why only a proportion of genetically
susceptible individuals may end up manifesting the disease.
The complexity of such regulation and its impact on dis-
ease is exemplified by investigations on monozygotic
twins: despite sharing identical genetic material, the risk of
developing MS in a twin of an MS patient is only 25%,
although it remains higher than in dizygotic twins or non-
twin siblings [54]. Similarly, besides genetic predisposi-
tion, epigenetic factors appear to be important for the onset
of systemic lupus erythematosus (SLE), since monozygot-
ic twins are often discordant also for this disease [55]. To
assess the relative contribution of heritable vs nonheritable
influences on a variety of immunological parameters, a re-
cent work investigated responses of 210 healthy twin pairs
[56]. Interestingly, immune variation in this system was
dominated by nonheritable determinants, some of which
also became more divergent with age, suggesting a cumu-
lative effect of environmental exposure [56].
Despite the clear evidence of an environmental component
in disease development, it has not been easy to pinpoint
the exact impact of epigenetics in autoimmune diseases;
for example, a study investigating three monozygotic twin
pairs discordant for MS found no reproducible differences
in DNA methylation, single nucleotide polymorphisms or
gene expression in CD4+ T cells [57]. A more recent study
evaluated genetic and epigenetic determinants of 21
autoimmune diseases, observing that most causal variants
map to enhancers rather than protein-coding genes and
frequently coincide with regions bound by transcription
factors and depleted of nucleosomes [58]. On the other
hand, DNA methylation in cells of monozygotic twins dis-
cordant for the disease was also analysed in the case of type
1 diabetes (T1D), and the differentially methylated regions
included several genes involved in immune responses [59].
Interestingly, some of the DNA methylation sites associ-
ated with T1D could be detected years before clinically
overt T1D, suggesting a role in increasing the risk of devel-
oping this disease [59]. Changes in DNA methylation have
been demonstrated also in SLE patients, with T lymph-
ocytes from these patients showing overall genomic hy-
pomethylation compared with controls [55]. Most import-
antly, exposing T cells to demethylating drugs resulted in
the induction of a lupus-like disease in mice [60]. Although
the mechanisms by which hypomethylated T cells induce
SLE are not fully understood, recent evidence points to-
wards a possible dominant role for IL-10 and IL-17 pro-
duction in T cells, dependent on altered methylation status
at these loci [61, 62]. Altered global DNA methylation and
dysregulation at specific genetic loci have also been re-
ported for rheumatoid arthritis (reviewed in [63, 64]), al-
though a comprehensive view of the role of DNA methyla-
tion in autoimmunity and whether in each case it represents
a cause or consequence is still lacking.
DNA methylation in disease: cause, consequence or
correlation?
Aberrant DNA methylation is a pervasive feature of human
tumours, which often show extensive genomic hypo-
methylation together with hypermethylation of tumour-
suppressor genes (reviewed in [65]). As cancer progresses,
the level of global methylation decreases, and DNA hypo-
methylation may contribute to cancer progression through
chromosomal instability, reactivation of transposable ele-
ments and loss of imprinting [65]. Vice versa, hypermethyl-
ation of tumour-suppressor genes can have a major impact
in suppressing the expression of these genes and therefore
unleash uncontrolled cell proliferation. Similarly, global
loss of 5hmC is a hallmark of a number of different tu-
mours [66-68], although in spite of the diagnostic and pro-
gnostic implications, the clear biological significance of
such altered methylation patterns remains to be fully under-
stood. Importantly, alterations in the distribution of histone
modifications have been described for a number of autoim-
mune diseases [63], and given the interplay between post-
translational modification of histones and DNMT enzymes
[69], at least part of the altered DNA methylation patterns
observed in disease may potentially be linked to histone
modifications.
While a causal link between mutations in DNA-modifying
enzymes, altered methylation patterns and disease has been
worked out in some cases [7, 8, 66], it has to be highlighted
that some biological consequences of altered methylation
do not necessarily link directly to disease. Indeed, changes
in DNA methylation and hydroxymethylation are imper-
fectly maintained during replication and are subject to con-
siderable epigenetic drift, that is, gradual increase or de-
crease at specific loci [70]. Such stochastic drift not only
creates epigenetic mosaicism within populations, but it is
also part of the normal process of aging, with aging cells
and tissues showing considerable DNA hyper- or hypo-
methylation over time [70, 71]. Moreover, while some
mouse models lacking DNMT3a or TET2 develop haema-
topoietic malignancies [7, 8, 30, 31, 33], this is not the
case for mice lacking other DNMT or TET family mem-
bers, suggesting that altered methylation patterns do not ne-
cessarily lead straight to disease. They can however pre-
dispose to its onset, and the lack of DNMT3a in particular
appeared to confer flexibility to the methylome of haema-
topoietic stem cells, allowing cellular transformation after
the acquisition of additional mutations [7, 8].
Interestingly, although the underlying mechanism remains
unclear, chronic inflammation can be an important inducer
of epigenetic drift, and potentially predisposing to the onset
of disease. For example, Helicobacter pylori is a well-
known inducer of chronic inflammation and gastric cancer,
and altered patterns of DNA methylation are associated
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with H. pylori infection. In a gerbil model of gastric cancer,
H. pylori infection was sufficient to induce DNA methyla-
tion in gastric epithelial cells, which could be partially re-
versed by H. pylori eradication or blocked by immunosup-
pressive drugs [72], suggesting that inflammation induced
by the infection was a critical determinant of hypermethyl-
ation. Other determinants of methylation variations remain
poorly understood [70].
MicroRNAs, immune regulation and
autoimmunity
MicroRNAs have recently emerged as important regulators
of both transcriptional and epigenetic programmes, with
pivotal roles in regulating early T cell development, lineage
specification and function [73]. As a result of their stability,
miRNAs are most suitable to maintain memory of altered
cellular states [3] and it is becoming increasingly clear that
they are involved in regulating various aspects of autoim-
munity (reviewed in [74, 75]), as well as in the regulation
of DNA-modifying enzymes. For instance, miR-21 and
miR-148a were shown to be highly expressed in patients
with SLE, and to promote hypomethylation by repressing
DNMT1 expression [76]. This in turn led to increased ex-
pression of autoimmune-associated genes like CD70 and
LFA-1, surface markers that were shown to play a role in
lupus [55].
A growing number of studies also identified miRNAs as
potential novel therapeutic targets in animal models of MS
as well as in primary cells derived from MS patients (table
1). For example, miR-155 and miR-29ab expression was
found to be elevated in mouse CD4+ T cells during ex-
perimental autoimmune encephalomyelitis (EAE), and
miR-155– or miR-29ab–deficient mice had a delayed
course and reduced severity of disease [77, 78]. Another
relevant example is provided by miR-326, whose expres-
sion was highly correlated with disease severity in patients
with MS and in mice with EAE. Accordingly, modulation
of miR-326 expression altered disease severity [79]. Vice
versa, miR-20 was shown to be downregulated during
Figure 3
Interplay between miRNAs and the DNA methylation
machineries. MiRNAs are both target and effector of epigenetic
modifications. Expression of miRNAs can be modulated by levels of
DNA methylation in the gene locus of any given miRNA. In turn,
mature miRNAs bind the 3’UTR of target mRNAs leading to a
reduction in protein output. DNMT and TET mRNAs can be
targeted by miRNAs such as miR-29, miR-22 and others, thereby
modulating the levels of DNA methylation and hydroxymethylation.
DNMT = DNA methyltransferase; miRNA = micro RNA; mRNA =
messenger RNA; TET = ten-eleven translocation protein; UTR =
untranslated region
Table 1: Common miRNAs dysregulated in autoimmune diseases. Examples of some common miRNAs that have been reported to influence autoimmunity in general,
MS or its experimental model (EAE) in humans (Hsa), mouse (Mmu) or rat (Rno).
miRNA Expression change Target/ Function Model system Outcome PMID
–
(Dicer/Drosha
deletions)
All miRNAs down Elimination of components of the miRNA
machinery in Tregs
Mmu Fatal autoimmunity 18725525
18725526
18725527
Let-7e Up Dysregulated cytokine production Mmu Silencing ameliorated EAE 23079871
miR-10 Up Bcl-6, T cell plasticity Mmu Delayed onset of EAE 22544395
miR-17~92 Up Treg functions Mmu Treg-specific loss of miR-17~92
results in exacerbated EAE
23858035
20148420
miR-20b Down Disease severity, Th17 responses Mmu Overexpression leads to reduced
severity of EAE
24842756
miR-23b Down Suppresses inflammatory cytokine-mediated
signaling
Hsa/ Mmu Overexpression leads to reduced
severity of EAE
22660635
miR-29 Up in MS and EAE T-bet, IFNg, Th1 differentiation Hsa/ Mmu Knock-out mice have reduced EAE 22772450
miR-132/212 Up Th17 differentiation Mmu Exacerbated EAE 23818645
miR-155 Up Positive regulator of inflammation Mmu Knock-out mice have reduced EAE 20888269
21788439
miR-181 Up Regulates threshold of TCR activation Hsa/ Rno Upregulated in CD4+ T cells of
strains susceptible to EAE and in
cerebrospinal fluid of MS patients
17382377
25775432
23514736
23077021
miR-301 Up Th17 differentiation Mmu Exacerbated EAE 22517757
miR-326 Up Disease severity, Th17 responses Hsa/ Mmu Expression correlates with disease 19838199
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EAE, and its overexpression led to reduced disease severity
in mice [80].
In MS patients, distinct miRNA expression profiles were
found in CD4+ and CD8+ T cells as well as B cells as
compared with healthy donors, and miR-17-5p, another
miRNA known to be involved in autoimmunity, was up-
regulated in CD4+ T cells from MS patients [81]. Further
highlighting the importance of miRNAs in regulating vari-
ous aspects of human disease, a role has even been pro-
posed in the regulation of blood-brain barrier endothelial
tightness in MS patients [82]. Moreover, miRNAs have
been investigated as promising biomarkers for disease, be-
ing able to discriminate MS from other neurological dis-
eases, as well as different disease courses of MS [83].
Despite encouraging results underscoring the role of
miRNAs in autoimmune diseases, the biological function
of most of these miRNAs and their relevance for disease
in the context of MS is mostly unknown. MiR-181a is a
miRNA known to regulate the threshold of TCR activation
in developing thymocytes and to contribute to positive se-
lection in the thymus [84–86]. Interestingly, miR-181a was
found to be elevated upon EAE induction in lymph nodes
of EAE-susceptible Dark Agouti rats as compared with the
EAE-resistant rat strain Piebald Virol Glaxo [87]. Anoth-
er miRNA of the same family, miR-181c, was shown to
be increased in the cerebrospinal fluid of patients with MS
compared with other neurological diseases, and to differ-
entiate relapsing-remitting from secondary progressive MS
courses [83]. MiR-181c‒containing extracellular vesicles
were also shown to trigger the breakdown of the blood-
brain barrier in a model of brain metastatic cancer [88].
Finally, miR-181b was shown to be elevated in CD4+ T
cells from SLE patients, as compared with healthy con-
trols, in a manner that was potentially linked to DNA hy-
pomethylation in these patients [89]. To understand the
biological relevance of this miRNA in regulating the ac-
tivation and function of T cells, and therefore a possible
role in disease onset or progression, our lab investigated
the role of miR-181a in the activation of primary human T
cells upon recognition of specific antigens [90]. We found
that miR-181a expression regulated the threshold of ac-
tivation of primary human T helper cells, especially of
the Th17 type, known to be involved in MS pathogenesis
[35, 37]. Moreover, we showed that, given two memory T
cells bearing the same identical TCR (therefore with the
same antigen recognition capacity), the cell expressing the
highest levels of miR-181a became able to respond with
full-blown activation and overt proliferation to the lowest
concentrations of cognate antigen, regardless of the pheno-
type, strongly suggesting the possibility that miRNAs may
also be important regulators of the threshold of T cell re-
sponses toward autoantigens in autoinflammatory diseases
[90]. More studies in this direction will enable us to under-
stand the specific roles played by these regulatory molec-
ules in the modulation of autoimmune responses.
Interplay between DNA-modifying enzymes and
miRNAs
To fully grasp the level of complexity of the mechanisms
involved in fine-tuning the regulation of gene expression,
one should also consider the interplay between DNA
methylation and miRNA expression. Indeed, miRNAs can
play a role in the modulation of DNA methylation both as
targets (that is, DNA methylation can alter miRNA expres-
sion and consequently expression of downstream genes)
and as effectors (that is, miRNAs reduce the expression of
target DNA-modifying enzymes) (fig. 3).
For instance, the miR-29 family was shown to target
DNMT1, DNMT3a and DNMT3b, leading to global DNA
hypomethylation and re-expression of tumour suppressor
genes in acute myeloid leukaemia cells [91]. Interestingly,
miR-29 family members were also shown to be able to tar-
get TET enzymes, suggesting that this family of miRNAs
acts primarily by protecting cells against perturbations in
the existing DNA methylation landscape [92]. Similarly,
miR-22 was shown to target directly TET proteins and to
contribute to leukaemia development and metastatic poten-
tial of cancer cells [93, 94]. By utilising an unbiased high-
throughput 3’ untranslated region activity screen of 460
miRNA constructs, a recent work showed that TET2 is un-
der extensive regulation by more than 30 miRNAs (includ-
ing miR-29b, miR-29c, miR-101, miR-125b, and miR-7)
able to reduce TET2 expression and levels of genomic 5h-
mC and to disrupt normal haematopoiesis [95].
Looking at the molecular interplay between DNA methyl-
ation and miRNAs in the opposite direction, the list of
miRNA genes that can be silenced by DNA methylation,
especially in cancer, is constantly growing [96], and given
the impact of miRNAs in regulating virtually every single
aspect of T cell biology [73], it would not be surprising to
identify miRNAs whose methylation-dependent silencing
leads to dysregulated immune responses.
An interesting aspect of miRNA-mediated regulation is
also related to the fact that selected miRNAs can be ex-
changed through exosomes during immune synapse form-
ation between T cells and antigen-presenting cells (APCs)
[97]. The flow of exchange was shown to be unidirectional,
from the T cell to the APC, and to be able to influence
gene expression in the recipient cell. Such mechanism of
exchange was also shown to occur between Tregs and vari-
ous immune cell types, and to suppress proliferation and
cytokine secretion by pathogenic Th1 cells [98]. Import-
antly, miRNAs were transferred to Th1 cells both in vitro
and in vivo, and such transfer significantly contributed to
suppression and prevention of systemic inflammation in
mice [98]. Whether exosome-mediated miRNA exchange
is also able to modulate the epigenetic status of the receiv-
ing cell remains to be evaluated, and is an exciting ques-
tion that will undoubtedly be addressed in work to come
(box 1). Intriguingly, RNA molecules can also be methyl-
ated, and methylation of primary miRNAs (pri-miRNAs)
was recently shown to act as a post-transcriptional mark
promoting further miRNA processing [99]. Whether such
‘‘epitranscriptomic’’ modifications [100] will become rel-
evant also in the context of disease will be an exciting topic
for the future.
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Box 1: Future challenges and outstanding questions
- What is the pattern of DNA methylation and hydroxymethylation in
T cells in vivo?
- How does epigenetic variation impact disease? Is there a role for
5hmC in autoimmune diseases?
- What are the mechanisms that dictate the activity of DNA-modify-
ing enzymes at specific genomic loci?
- Are there any DNA methylation-independent functions for DNMT
and TET proteins?
- Are small molecules interfering with 5hmC dynamics going to be
effective and useful in the clinic?
- Are miRNAs able to significantly alter the epigenome in vivo and in
disease?
Diet and metabolism
T cell metabolism
The role of metabolism in regulating T cell differentiation
and function is becoming increasingly clear (reviewed in
[101, 102]). Specifically, naïve, antigen-inexperienced T
cells have a quiescent metabolism and generate energy
primarily through oxidative phosphorylation (OXPHOS).
Upon activation, effector T cells undergo a profound meta-
bolic reprogramming and induce aerobic glycolysis, which
is energetically less efficient, but supplies metabolic in-
termediates for biosynthesis of molecules required to sus-
tain intense proliferation. Finally, memory T cells preferen-
tially engage OXPHOS fuelled by the catabolism of fatty
acids [101]. Metabolic pathways can also bias T helper
cell differentiation towards specific subsets, thereby poten-
tially influencing the outcome of an inflammatory response
or autoimmune pathology [103]. Given the importance of
metabolic pathways in regulating T cell responses, it is not
surprising that pharmacological inhibition of some crucial
metabolic regulators such as AMPK (AMP-activated pro-
tein kinase) have shown some effects in mouse models of
EAE [102]. While the rodent models of EAE are extremely
useful to dissect the mechanisms leading to or exacerbating
disease, confirmation in the human system will be required
to translate such potentially important findings to the clinic.
Dietary habits and epigenetic modifications
There is currently a great deal of interest regarding the pos-
sible link between diet, epigenetic modifications and dis-
ease. Vitamins and trace elements are important cofactors
of a wide variety of enzymes as well as donors of chemical
groups for epigenetic modifications. Folate is an essential
B vitamin whose derivatives are main effectors in methyl-
ation reactions. Specifically, derivatives of folate are cru-
cial to maintain appropriate methionine levels in the cells,
which in turn is utilised to generate S-adenosylmethionine
(SAM), the universal donor of methyl group [104]. Dietary
folate intake is one of the few established links between
diet and epigenetic modifications in both mouse (such as
in the Agouti mouse model) and humans, as shown in rural
Gambian women whose diet changes drastically accord-
ing to the rainy and dry seasons [105, 106]. These studies
showed that maternal folate intake is able to impact the es-
tablishment on 5mC patterns in the offspring.
Vitamin C is an essential nutrient for humans and primates,
which have lost the capacity to synthesise it from glucose.
Vitamin C acts as an antioxidant, able to maintain the
redox state of iron-containing enzymes, and consequently
to maintain the activity of dioxygenases such as TET en-
zymes [107]. As a result, vitamin C treatment of cultured
cells led to a striking increase in the levels of genomic 5h-
mC, strongly influencing gene expression and differenti-
ation potential [108]. However, whether altered levels of
these cofactors can impact directly immune responses re-
mains unclear. Vice versa, among the environmental factors
known to impact the risk of MS are levels of vitamin D,
whose serum levels are inversely correlated with the risk
of MS. Vitamin D also appears to influence the course of
MS, as lower levels are associated with increased severity
of the disease [109]. Despite the fact that dietary habits and
environmental factors can clearly have an influence of epi-
genetic modifications as well as on disease susceptibility,
a precise link between these factors is still somewhat loose
and the magnitude of these effects remains to be fully de-
termined.
Epigenetic “resetting” of
autoimmunity?
Although two major demethylating agents (decitabine and
its analogue azacitidine) are now commonly used in the
clinic for treatment of myelodysplastic syndrome and some
leukaemias, the mechanisms underlying their clinical effic-
acy remain to be fully elucidated [110]. While genetic alter-
ations are permanent, epigenetic modifications are poten-
tially reversible, opening the possibility to utilise epigen-
etic drugs to at least relieve a certain phenotype. One of
the major obstacles in this direction is, however, linked to
the fact that there is still a paucity of information about the
impact on disease of global changes in methylation versus
gene-specific alterations. For example, despite the global
hypomethylation observed in SLE patients, gene-specific
hypermethylation cannot be ruled out. Moreover, the im-
pact of other DNA modifications, such as 5hmC and its fur-
ther products of oxidation, on gene transcription and dis-
ease remains for the most part to be uncovered. In general,
a better understanding of the mechanisms that drive aber-
rant methylation and their pathological importance will be
crucial to be able to exploit them for therapeutic purposes.
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Figures (large format)
Figure 1
DNA methylation and hydroxymethylation. Cytosine modifications in DNA have functional consequences on gene expression. (a) Cytosine
can be methylated by DNMT enzymes to give rise to 5mC, which can be oxidised by TET enzymes to 5hmC and further products (5fC and
5caC). In an active demethylation pathway, these products of TET enzymatic activity are likely to be excised and repaired by the thymine-DNA
glycosylase enzyme and base excision repair mechanisms to regenerate the unmodified cytosine. Methylated DNA can be recognised by MBD
proteins that can recruit histone modifying complexes (HMTs and HDACs). (b) DNA methylation occurs at regulatory regions (such as
promoters), but also in gene bodies. DNMT enzymes are responsible for 5mC deposition, often resulting in the transcriptional repression of the
methylated promoter. TET proteins activity can lead to demethylation with a potential for transcriptional activation.
5caC = 5-carboxylcytosine; 5fC = 5-formylcytosine; 5hmC = 5-hydroxymethylcytosine; 5mC = 5-methylcytosine; BER = base excision repair;
DNMT = DNA methyltransferase; HDAC = histone deacetylase; HMT = histone methyltransferase; MBD = methyl-CpG-binding domain protein;
TDG = thymine-DNA glycosylase; TET = ten-eleven translocation
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Figure 2
DNA methylation dynamics regulate cytokine production in T lymphocytes. DNA methylation modulates cytokine production upon T cell
activation, and active demethylation processes (independent of cell replication) have been shown to act at some cytokine loci. Hypothetically,
these processes may involve TET proteins as an underlying mechanism of demethylation.
5hmC = 5-hydroxymethylcytosine; 5mC = 5.methylcytosine; IFNγ = interferon-gamma; IL = interleukin; TET = ten-eleven translocation
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Figure 3
Interplay between miRNAs and the DNA methylation machineries. MiRNAs are both target and effector of epigenetic modifications.
Expression of miRNAs can be modulated by levels of DNA methylation in the gene locus of any given miRNA. In turn, mature miRNAs bind the
3’UTR of target mRNAs leading to a reduction in protein output. DNMT and TET mRNAs can be targeted by miRNAs such as miR-29, miR-22
and others, thereby modulating the levels of DNA methylation and hydroxymethylation.
DNMT = DNA methyltransferase; miRNA = micro RNA; mRNA = messanger RNA; TET = ten-eleven translocation protein; UTR = untranslated
region
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